The role of effective filtration area in regulating aqueous outflow facility and intraocular pressure by Ren, Ruiyi
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2018
The role of effective filtration area
in regulating aqueous outflow















THE ROLE OF EFFECTIVE FILTRATION AREA IN REGULATING AQUEOUS 













B.S., Peking University, 2000 
M.A., Boston University, 2005 







Submitted in partial fulfillment of the 
 
requirements for the degree of 
 











































 Ruiyi Ren 







First Reader ___________________________________________________ 
 Haiyan Gong, M.D., Ph.D. 
 Professor of Ophthalmology and Anatomy & Neurobiology 
 
 
Second Reader ___________________________________________________ 
 Andrew W. Taylor, Ph.D. 




















First and foremost, I would like to thank my PI, Dr. Haiyan Gong. She took 
a chance on me years ago by accepting me into her lab and lately offered me the 
chance to pursue the doctoral degree in Anatomy and Neurobiology. I had no 
experience in glaucoma research at that time, nor any experience in eye 
perfusion or mouse studies. Through our work and collaborations, we conducted 
innovative research that broadened the scope of our knowledge on aqueous 
outflow regulation. I would like to thank past and present members of the Gong 
lab, especially Thuy Duong Le, David Swain, Julia Lai, and Dr. Laiyin Ma, who 
contributed to the data presented in this dissertation thesis; also Dr. Chen-Yuan 
Yang and Elliot Cha, who taught me various important techniques that are 
necessary for me to conduct my research. 
 I would like to thank my entire thesis committee. Thank you Dr. Douglas 
Rosene for being my committee chair and providing me with guidance on the 
final stages of my doctoral career. Dr. Andrew Taylor, thank you for providing 
critical and inspiring comments for my experimental design and data analyses. 
Also, thank you for being the second reader for my dissertation. I would like to 
thank Dr. Kathleen Rockland and Dr. Maria Medalla for not only raising critical 
and helpful questions, but also being willing to help me find the solutions. Thank 
you both for helping me to think outside the box. Finally, I would like to thank Dr. 
 vi 
Noorjahan Panjwani for sharing very helpful experience on mouse study with me, 
as well as your emotional support and encouragement. 
 I would like to thank the Anatomy and Neurobiology Department, 
especially Dr. Mark Moss, Dr. Jennifer Luebke, and Melissa Kelly for their 
enormous help under various conditions. I would also like to thank Dr. Tarik 
Haydar, who kindly allowed me to use his lab equipment.  
 I would like to thank the Ophthalmology Department, especially Dr. 
Sharmila Masli for generously providing the gene knock-out mice used in 
presented study in this thesis. Thank you Dr. Tatfong Ng for always helping me 
with troubleshooting for my experiments and teaching me various techniques.  
 Last but not least, I would like to thank my family and friends for their 
unconditional support. I would not have made it through this program without 
their love and encouragement. 
  
 vii 
THE ROLE OF EFFECTIVE FILTRATION AREA IN REGULATING AQUEOUS 
OUTFLOW FACILITY AND INTRAOCULAR PRESSURE 
RUIYI REN 
Boston University School of Medicine, 2018 
Major Professor: Haiyan Gong, M.D., Ph.D., Professor of Ophthalmology and 
Anatomy and Neurobiology 
ABSTRACT 
Primary open angle glaucoma (POAG) is a leading cause of blindness 
worldwide. Elevated intraocular pressure (IOP), resulting from increased 
aqueous humor outflow resistance, is a major risk factor for the development and 
progression of POAG. Outflow resistance in the trabecular outflow pathway is 
mainly (50-75%) generated in the juxtacanalicular connective tissue (JCT), and 
partially (25-50%) in the portion distal to the inner wall of Schlemm’s canal. The 
details of how aqueous humor flows through these tissues and how resistance in 
these tissues is regulated are not fully understood in normal and POAG eyes. 
Aqueous humor outflow was shown to be “segmental”, with discontinuous active 
regions of aqueous humor filtration along the trabecular outflow pathway that can 
be labeled with perfused fluorescent tracers and measured as effective filtration 
area (EFA). In this study, we investigated the relationship between changes in 
EFA along the trabecular outflow pathway and outflow facility/IOP under two 
experimental conditions. The first experiment was designed to increase outflow 
facility by using netarsudil, a recently approved Rho kinase inhibitor class 
 viii 
glaucoma medication, in normal human donor eyes. The second experiment was 
designed to increase IOP with topical steroid treatment for 5 weeks in mice. The 
purpose of this study is to verify whether EFA can be modulated by netarsudil or 
steroid treatment and to demonstrate the morphological changes that may be 
responsible for the changes of EFA. We analyzed EFA along the trabecular 
outflow pathway and found that elevated/reduced EFA correlated with increased 
outflow facility/IOP. Guided by EFA, we performed detailed morphological 
comparison between the active and inactive portions of aqueous humor filtration 
tissue to evaluate possible structural changes involved in EFA regulation. We 
found that increased EFA was associated with a loosened JCT structure and 
dilated episclearal veins, while decreased EFA was associated with a compacted 
JCT structure, increased deposition of curly collagen and/or fibrillary structure in 
the trabecular meshwork, and increased basement membrane continuity. Our 
data suggest that the netarsudil/steroid-induced morphological changes in the 
trabecular outflow pathway can result in either an increase or decrease in EFA, 




TABLE OF CONTENTS 
 
DEDICATION ................................................................................................................... iv 
ACKNOWLEDGMENTS .................................................................................................. v 
TABLE OF CONTENTS ................................................................................................. ix 
LIST OF TABLES ............................................................................................................ xi 
LIST OF FIGURES......................................................................................................... xii 
LIST OF ABBREVIATIONS .......................................................................................... xv 
CHAPTER ONE: General Introduction ......................................................................... 1 
1-1: Primary Open Angle Glaucoma ......................................................................... 1 
1-2: Functional Anatomy of Aqueous Outflow Pathway ......................................... 2 
1-3: Segmental Aqueous Outflow ............................................................................ 11 
1-4: Current Glaucoma Medications ....................................................................... 13 
1-5: Rho Kinase Inhibitor Netarsudil (AR-13324) .................................................. 15 
1-6: Steroid-induced Ocular Hypertension ............................................................. 19 
1-7: Thesis objectives ................................................................................................ 22 
CHAPTER TWO: Netarsudil Increases Outflow Facility in Human Eyes through 
Multiple Mechanisms ..................................................................................................... 25 
2-1: Introduction .......................................................................................................... 25 
2-2: Materials and Methods ...................................................................................... 27 
2-3: Results ................................................................................................................. 43 
 x 
2-4: Discussion ........................................................................................................... 64 
CHAPTER THREE: Reduced Effective Filtration Area in the Trabecular 
Meshwork of Steroid-induced Ocular Hypertensive Mouse Eyes .......................... 72 
3-1: Introduction .......................................................................................................... 72 
3-2: Methods ............................................................................................................... 73 
3-3: Results ................................................................................................................. 89 
3-4: Discussion ......................................................................................................... 116 
CHAPTER FOUR: Additional Studies and Future Researches ............................ 128 
4-1: Sphingosine-1-phosphate (S1P) reduces outflow facility Introduction. ... 128 
4-2: Steroid-induced ocular hypertension can be rescued by either topical 
administration of Rho kinase inhibitor or suspension of steroid treatment. .... 140 
4-3: Steroid-induced ocular hypertension is reversible by suspension of steroid 
treatment.................................................................................................................... 148 
4-4: Thrombospondin 1 (TSP1) may be involved in steroid-induced ocular 
hypertension.............................................................................................................. 166 
CHAPTER FIVE: General Discussion ...................................................................... 178 
JOURNAL ABBREVATIONS ...................................................................................... 188 
BIBLIOGRAPHY ........................................................................................................... 192 




LIST OF TABLES 
Table 2-1. Outflow facility change over time.. ..................................................... 45 
Table 4-1. Outflow facility change over time in human eyes.. ........................... 136 




LIST OF FIGURES 
 Figure 1-1. Aqueous outflow pathways... ............................................................. 3 
 Figure 1-2. Trabecular meshwork... ..................................................................... 7 
 Figure 1-3. Schematic diagram of rho/rho kinase signaling pathway and the role 
of rho kinase inhibitor... ............................................................................... 16 
 Figure 2-1. Global Image Analysis... .................................................................. 30 
 Figure 2-2. Confocal Image Analysis... .............................................................. 37 
 Figure 2-3. Light and Electron Microscopic Analyses... ..................................... 41 
 Figure 2-4. Outflow Facility... ............................................................................. 46 
 Figure 2-5. Episcleral Vein Percentage Effective Filtration Length (ESV PEFL) 
and Inner Wall (IW) PEFL... ......................................................................... 49 
 Figure 2-6. Trabecular Meshwork (TM) Thickness... ......................................... 52 
 Figure 2-7. Size of Episcleral Veins (ESVs)... .................................................... 56 
 Figure 2-8. Juxtacanalicular Connective Tissue (JCT) Thickness... .................. 58 
 Figure 2-9. Characteristic morphologies in high tracer regions in both netarsudil-
M1-treated and untreated eyes... ................................................................ 61 
 Figure 3-1. Dissection Methods and Imaging Planes......................................... 78 
 Figure 3-2. Measurements Methods... ............................................................... 81 
 Figure 3-3. IOP Change... .................................................................................. 92 
 Figure 3-4. Trabecular Meshwork Percentage Effective Filtration Length (TM 
PEFL)... ....................................................................................................... 94 
 Figure 3-5. Tracer Amount in Trabecular Meshwork.......................................... 98 
 xiii 
 Figure 3-6. Trabecular Meshwork Thickness.... ............................................... 101 
 Figure 3-7. Juxtacanalicular Connective Tissue (JCT) Thickness.... ............... 103 
 Figure 3-8. Extracellular Matrix Morphology in both Dexamethasone-Treated and 
Control Eyes.... .......................................................................................... 108 
 Figure 3-9. Basement Membrane Continuity by Immunohistochemistry.... ...... 110 
 Figure 3-10. Basement Membrane Continuity by Using Electron Microscopy....
 .................................................................................................................. 112 
 Figure 3-11. Correlation between Intraocular Pressure and TM PEFL.... ........ 118 
 Figure 4-1. S1P induced outflow facility change in bovine eyes.... .................. 133 
 Figure 4-2. S1P induced outflow facility and outflow pattern change in human 
eyes.... ....................................................................................................... 137 
 Figure 4-3. Effects of Rho-kinase inhibitor AR12286 and the suspension of 
dexamethasone treatment on elevated IOP.... .......................................... 145 
 Figure 4-4. Effects of long-term suspension of dexamethasone treatment on 
elevated IOP.... .......................................................................................... 150 
 Figure 4-5. Suspension of dexamethasone treatment restores the TM PEFL in 
mouse eyes.... ........................................................................................... 152 
 Figure 4-6. Suspension of dexamethasone treatment restores the tracer amount 
in trabecular meshwork.... ......................................................................... 156 
 Figure 4-7. Suspension of dexamethasone treatment increases trabecular 
meshwork thickness.... .............................................................................. 159 
 xiv 
 Figure 4-8. Suspension of dexamethasone treatment restores Juxtacanalicular 
Connective Tissue (JCT) Thickness.... ...................................................... 161 
 Figure 4-9. Immunohistochemistry staining of TSP1 and TGFβ2.... ................ 170 
 Figure 4-10. Dexamethasone-induced IOP elevation was partially inhibited in 
TSP1-null mice.... ...................................................................................... 172 
 Figure 5-1. Illustration of Outflow Pattern through the Juxtacanalicular 





LIST OF ABBREVIATIONS 
ANOVA .................................................................................... analysis of variance 
BM ........................................................................................ basement membrane 
BSA ..................................................................................... bovine serum albumin 
CC ............................................................................................... collector channel 
CS ........................................................................................ Compound Symmetry 
CTM ................................................................. corneoscleral trabecular meshwork 
DAPI ......................................................................... 4',6-diamidino-2-phenylindole 
DF ............................................................................................ degrees of freedom 
DMSO ......................................................................................... dimethyl sulfoxide 
ECM ......................................................................................... extracellular matrix 
EFA ..................................................................................... effective filtration area 
ER ....................................................................................... endoplasmic reticulum 
ESVs .............................................................................................. episcleral veins 
EVP .............................................................................. episcleral venous pressure 
Ex/Em ................................................. excitation wavelength/emission wavelength 
F-actin ......................................................................................... filamentous actin 
FL .............................................................................. fluorescent-decorated length 
GPBS .......... Dulbecco’s phosphate-buffered saline containing 5.5 mM D-glucose 
GTP .................................................................................. guanosine tri-phosphate 
GV ..................................................................................................... giant vacuole 
hr ..................................................................................................................... hour 
 xvi 
IACUC ............................................. Institutional Animal Care and Use Committee 
IOL .................................................................................................. intraocular lens 
IOP .......................................................................................... intraocular pressure 
ISP .............................................................................................. intrascleral plexus 
IW ............................................................................................................ inner wall 
JCT .................................................................... juxtacanalicular connective tissue 
LED .......................................................................................... light emitting diode 
LIMK ...................................................................................................... LIM-kinase 
LS mean .................................................................................... least square mean 
µl............................................................................................................... microliter 
µm ........................................................................................................ micrometer 
µM ......................................................................................................... micromolar 
min ................................................................................................................minute 
mL .............................................................................................................. milliliter 
MLC ............................................................................................ myosin light chain 
mm .......................................................................................................... millimeter 
mM .......................................................................................................... millimolar 
mm Hg ................................................................................. millimeters of mercury 
MMPs .............................................................................matrix metalloproteinases 
NET .............................................................................. norepinephrine transporter 
nl ................................................................................................................nanoliter 
nm ......................................................................................................... nanometer 
 xvii 
OCT ........................................................................ optical coherence tomography 
PBS ............................................................................... phosphate-buffered saline 
PEFL .................................................................... percent effective filtration length 
pH .............................................................................................. potential hydrogen 
POAG ...................................................................... primary open angle glaucoma 
REML ...................................................................... restricted maximum likelihood 
ROCK ..................................................................................................... rho kinase 
SE ..................................................................................................... standard error 
sec ............................................................................................................... second 
SEM .............................................................................. standard error of the mean 
SC ............................................................................................... Schlemm’s canal 
siRNA ................................................................................... small Interfering RNA 
SPARC ........................................... Secreted Protein, Acidic and Rich in Cysteine 
S1P .................................................................................Sphingosine-1-phosphate 
TFL ................................................................................. total tracer-labeled length 
TGFβ2 .............................................................. Transforming growth factor-beta 2 
TIMPs .......................................................... tissue inhibitors of metalloproteinases 
TL .......................................................................................................... total length 
TM ......................................................................................... trabecular meshwork 
TSL ............................................................................................ total scleral length 
TSP1 ........................................................................................ Thrombospondin 1 
UTM .............................................................................. uveal trabecular meshwork 
 xviii 
VE-cadherin .............................................................. vascular endothelial cadherin 
vol/vol (v/v) ........................................................................... volume : volume ratio 






CHAPTER ONE: General Introduction 
 
1-1: Primary Open Angle Glaucoma 
 Glaucoma is the second most common cause of blindness and the third 
most common cause of visual impairment worldwide.1 Primary open angle 
glaucoma (POAG) is the major type of glaucoma, accounting for 74% of all 
glaucoma cases.2 In this form, the anterior chamber angle between the cornea 
and iris leading to the outflow drainage tissues remains open. In contrast, in 
primary angle-closure glaucoma, drainage of the aqueous humor becomes 
physically blocked by the apposition of the iris against the cornea, often due to 
deformity of the iris.3 The number of people affected by POAG in the United 
States was 2.71 million in 2011, which is expected to increase to 7.32 million by 
2050.4,5  
Elevated intraocular pressure (IOP), resulting from increased resistance to 
aqueous humor outflow, is a major risk factor for the development and 
progression of POAG.6,7 Other risk factors include age,2,8,9 ethnic 
background,2,9,10 a positive family history for glaucoma,11,12 high myopia,13 and 
gender.2,9–11 As a result of elevations in IOP, the optic nerve head degenerates. 
This neuronal degeneration in turn places stress on the axons of the ganglion 
cells of the retina, ultimately resulting in a progressive loss of the visual field. The 




multicenter clinical trials have demonstrated that reduction and tight control of 
IOP in patients can delay or prevent the progression of vision loss associated 
with POAG, including patients with IOP in the normal range at diagnosis.14–18 
Therefore, reduction of IOP via medical, laser, or surgical means remains the 
sole clinical objective for the treatment of this blinding disease.19,20  
 
1-2: Functional Anatomy of Aqueous Outflow Pathway 
IOP is maintained within a normal range through a dynamic balance of aqueous 
humor production and outflow.21,22 After being produced by the ciliary body in the 
posterior chamber, aqueous humor flows out of the eye via two pathways: the 
trabecular and the uveoscleral outflow pathways (Fig. 1-1). Although indirect 
estimation of uveoscleral outflow suggests that it may account for up to half of 
the aqueous outflow,23 direct measurements using a tracer show that under 
normal physiological conditions, the trabecular outflow pathway is the major 
outflow pathway, accounting for up to 90% of aqueous outflow in aged human 
eyes.24 In the trabecular outflow pathway, aqueous humor drains from the 
anterior chamber sequentially through the uveal and corneoscleral meshwork 
beams, juxtacanalicular connective tissue (JCT) region, and inner wall 
endothelial cells of Schlemm’s canal (SC) until finally entering the lumen of SC. 
From SC, aqueous humor drains into the collector channels, intrascleral plexus, 














Figure 1-1. Aqueous outflow pathways.  
A: Schematic diagram of aqueous outflow pathways. Aqueous humor is 
produced by the ciliary body and passes from the posterior chamber through the 
pupil into the anterior chamber into the trabecular meshwork, Schlemm’s canal, 
and finally into the episcleral venous system. The alternative path is the 
uveoscleral outflow that drains fluid through the ciliary muscle into the 
supraciliary and suprachoroidal spaces and then out of the eye through the 
sclera. Adapted from: Fan BJ and Wiggs JL, 2010.25 B: A light micrograph of the 
anterior chamber angle is shown. Major structures along the trabecular outflow 
pathways, including ciliary body (CB), anterior chamber, trabecular meshwork 
(TM), Schlemm’s canal (SC), collector channel (CC), intrascleral plexus (ISP), 
episcleral vein (ESV) are labeled. Scleral spur (SS) and iris are also labeled. 






outflow pathway, aqueous humor drains from the anterior chamber sequentially 
through the longitudinal muscle bundles of the ciliary body, supraciliary space, 
the suprachoroidal space, and through the sclera. From the sclera, aqueous 
humor flows into the lymphatics in the orbit outside of the eye. 
The trabecular meshwork (TM) is divided into three distinct regions (from the 
anterior chamber to SC): the uveal trabecular meshwork (UTM), the 
corneoscleral trabecular meshwork (CTM), and the juxtacanalicular tissue (JCT), 
which is directly adjacent to the inner wall endothelium of SC (Fig. 1-2). The UTM 
consists of an irregular trabeculae network structure arranged in one to three 
layers.27 The CTM consists of several interconnected sheets, extending from the 
scleral spur to the cornea and forming 8–15 trabecular layers.28 These trabecular 
layers in CTM are thicker, more organized, and more compact than those of the 
UTM. Each lamella or beam of the uveal or corneoscleral TM has an avascular 
core of collagen and elastin covered with a basal lamina and a single layer of 
endothelial cells. There are many intertrabecular spaces between the beams of 
the UTM and CTM, which consequently have a highly permeability and present 
little resistance to aqueous outflow.29 The JCT region is organized differently. 
The JCT cells are immersed in a relatively free loose connective tissue to form 
an irregular network. JCT cells form long processes to attach to one other and to 
ECM fibrils or to the inner wall cells of SC. The spaces between JCT cells and 














Figure 1-2. Trabecular meshwork.  
A: Schematic diagram of aqueous humor drainage through the trabecular 
meshwork. Aqueous outflow (red dashed line, with arrow head showing the 
direction of flow) drains through the trabecular meshwork (TM) by sequentially 
passing through the trabecular beams of the uveal TM (UTM), the lamellar 
corneoscleral meshwork (CTM), and the extracellular matrix of the 
juxtacanalicular connective tissue (JCT). The fluid then penetrates the inner wall 
(IW) endothelial cells by formation of intracellular giant vacuoles and pores that 
open into the lumen of Schlemm’s canal (SC). SC is connected to collector 
channels (CCs) leading to the intrascleral plexus (ISP) and episcleral veins 
(ESVs). Adapted from Pizzirani S and Gong H, 2015.30 B: A light micrograph of 
the trabecular meshwork is shown. UTM, CTM, JCT, IW, SC and CC are labeled. 







consisting of various proteoglycans and hyaluronan.31–33  The JCT contains a 
characteristic elastic-fiber network that connects to the inner wall endothelium of 
the SC.34 The anterior tendons of the ciliary muscle are inserted into this 
network,35,36 so that contraction of the ciliary muscle spreads the lamellar portion 
of the meshwork, widens the trabecular spaces, expands the area of filtration and 
thereby reduces the outflow resistance.36 In addition to ciliary muscle cells, 
contractile cells within the scleral spur (Fig. 1-1B) contain numerous actin 
filaments (α-smooth muscle actin) and express a myofibroblast-like phenotype, 
which very likely affects the TM tone.37 Scleral spur cells are innervated by 
varicose axons38 and form connections with the elastic fibers within the scleral 
spur, which are directly continuous with the elastic fibers in the TM and the 
elastic-fiber network in the JCT. Changes in scleral spur cell tone are likely to 
modulate outflow resistance by altering the architecture of the TM outflow 
pathways. Scleral spur cells are equatorially or circumferentially oriented, and 
their action on the geometry of the TM outflow pathways may well be 
antagonistic to that of the scleral-spur-attached ciliary muscle, which are 
longitudinally oriented. In support of this, an increase in TM cell tone is correlated 
with an increase in outflow resistance in bovine eyes.39 Moreover, Cells of the 
TM were reported to display smooth muscle-like properties including contractility, 
electromechanical characteristics, and expression of smooth muscle-specific 




In the TM, experimental evidence suggests that the majority of outflow 
resistance is generated in the JCT region7,43,44 and is modulated by the inner wall 
endothelial cells of SC and their pores45. However, experiments involving the 
complete removal of the TM7,46 or precisely removing portions of sclera distal to 
the outer wall of SC47 suggest that one-third to one-half of the total outflow 
resistance is located distal to SC. The mechanisms that regulate the aqueous 
outflow resistance in each of these regions have not been fully investigated in 
normal eyes.  
In glaucomatous eyes, elevation of IOP results from an abnormally increased 
resistance to outflow in the trabecular outflow pathway. The causes of this 
increased outflow resistance are also not fully understood, but current evidence 
supports an increase in the contractile tone and stiffness of the TM, changes in 
extracellular matrix (ECM) composition, and/or a decrease in the conductance of 
the IW of SC. 48–55 
 
1-3: Segmental Aqueous Outflow 
Previous tracer studies concluded that aqueous humor outflow is 
“segmental” rather than uniform,56–62 so that only a fraction of the total area of the 
outflow pathway is active in aqueous humor filtration at any given time. This 
active fraction of area was termed as effective filtration area (EFA). In order to 




measuring percent effective filtration length (PEFL) and a positive correlation was 
found between PEFL and outflow facility across three species (bovine, monkey, 
and human) with marked differences in the morphology of their outflow 
pathways.58,61,63 In addition, inner wall (IW) PEFL was decreased after acute and 
chronic elevation of IOP in bovine and monkey eyes.57,62,64 There was also an 
inverse relationship between the trabecular meshwork (TM) PEFL and IOP in a 
gene knock-out ocular hypotensive mouse model.65 These studies suggest that 
PEFL can serve as a critical morphometric parameter to correlate with outflow 
facility, allowing us to dissect the specific regions of the meshwork exhibiting 
different tracer density and further analyze the correlated morphological changes. 
Although the majority of outflow resistance was thought to be generated at the 
inner wall of SC and its underlying JCT, 7,43,44 some studies showed that one-
third to half of the resistance was located distal to the SC;7,46,47 therefore, 
regulation of aqueous outflow distal to the SC should also be investigated. 
Recently, a imaging technique was developed that enables the investigation on 
effective filtration area at three locations (proximal to the inner wall of SC, at the 
inner wall of SC, and distal to the SC) along the outflow pathway in donor human 
eyes by combining global imaging with confocal microscopy.56 With this 
technique, Cha et al. found that the outflow pattern proximal to the inner wall of 
SC (at TM) and distal to the SC (at ESVs) was also segmental, suggesting that 




along the trabecular outflow pathway, rather than limited in the JCT-IW region. 
Therefore, it is necessary to also investigate the EFA and correlated 
morphological changes in the locations along the trabecular outflow pathway 
other than the JCT-IW region. 
 
1-4: Current Glaucoma Medications 
Currently, reduction of IOP by medical, laser, or surgical means remains the 
only effective approach for the treatment of glaucoma (including normal tension 
glaucoma).14,66 The annual cost of topically administered eye drops and surgery 
in the USA was recently estimated to be around $1.9 billion, 38–52% of which is 
related to topical glaucoma medications.67 
Common medical therapies for glaucoma lower IOP by either decreasing 
production of aqueous humor or increasing aqueous outflow drainage. A recent 
study suggested that prostaglandin analogs are the most effective in lowering 
IOP, a reflection of the fact that these compounds are the most commonly 
prescribed eye-drop.68 These analogs induce significant increases in uveoscleral 
outflow69 and to a lesser extent, trabecular outflow.70,71 Prostaglandins are 
endogenously expressed throughout the anterior chamber and can cause 
decreases in TM cell contractility and outflow resistance.72–74 Although the 




facilitate aqueous outflow were not fully understood, experimental evidence 
suggested that they may increasing matrix metalloproteinases (MMPs) 
expression,75,76 and reduce the ECM between the ciliary muscle bundles.77–80 
Second-line medications include carbonic anhydrase inhibitors and β-blockers. 
Carbonic anhydrase inhibitors decrease aqueous humor production through 
chemical inhibition of bicarbonate formation,81 while β-blockers aid in the 
reduction of aqueous production by decreasing blood supply to the ciliary body 
via inhibiting β1- and/or β2-adrenoceptors.82,83 In addition, the chronic exposure 
to β-blockers can elevate prostaglandin expression and increase uveoscleral 
outflow.84,85 Cholinergic drugs are the third-line medications. These drugs 
facilitate ciliary muscle contraction via interacting with the cholinergic nerve 
terminals in ciliary muscles. Through their insertions into the elastic-fiber network 
in the TM and connecting SC, the ciliary muscle contraction increases trabecular 
outflow and decreases IOP by increasing trabecular space and SC lumen area, 
in turn allowing for increased aqueous fluid transport through the TM and across 
SC endothelial cells.86–88 Combination of these eye drops is usually used.  
Although the TM represents a major site of pathology in glaucomatous eyes, 
it is not the primary target for most of the glaucoma drugs currently on the 
market.89 These widely used topical medications mentioned above predominantly 
target uveoscleral outflow and mostly only influence the trabecular pathway by 




the diseased TM untreated, IOP often continues to rise over time due to 
continuous deterioration and dysfunction of the TM.90 Therefore, there is a critical 
need to develop new pharmacological agents that specifically target the 
trabecular outflow pathway, especially the JCT or cytoskeleton of cells of the 
outflow tissues. Rho kinase inhibitors, marine macrolides, adenosine- and 
prostanoid-receptor agonists together with siRNA formulations are all currently 
under evaluation. The most advanced of these are rho kinase (ROCK) inhibitors 
that have already been approved for use in Japan as well as in the USA. 
 
1-5: Rho Kinase Inhibitor Netarsudil (AR-13324) 
Rho kinase (ROCK) is a serine/threonine kinase that is involved in a wide 
range of cellular responses related to cell motility, from smooth-muscle 
contraction to cell migration and neurite outgrowth.91 When activated by GTP-
bound RhoA, ROCK phosphorylates and activates various intracellular 
molecules, including myosin light chain (MLC) phosphatase, LIM-kinase (LIMK), 
etc. When ROCK phosphorylates MLC phosphatase and inhibits its activity, it 
results in an increase in MLC phosphorylation and, consequently, an increase in 
stress fiber formation and actomyosin contraction in smooth muscle-like cells, 
including the myofibroblast-like cells of the TM.92–94 Activated ROCK contracts 
the smooth muscle of blood vessels, such as ISP and ESVs, which may cause 










Figure 1-3. Schematic diagram of rho/rho kinase signaling pathway and the 
role of rho kinase inhibitor.  
When activated by GTP-bound Rho protein, rho kinase (ROCK) phosphorylates 
myosin light chain phosphatase (MLCP) and inhibits its activity, resulting in an 
increase in myosin light chain (MLC) phosphorylation and, consequently, 
increasing actomyosin contraction in smooth muscle-like cells, including the 
myofibroblast-like cells of the trabecular meshwork (TM). Activated ROCK also 
contracts the smooth muscle of blood vessels [intrascleral plexus (ISP) and 
episcleral veins (ESVs)], which causes blood vessel constriction. Meanwhile, 
ROCK also phosphorylates and activates LIM kinase (LIMK), which in turn 
phosphorylates and inactivates cofilin, consequently inhibiting the 
depolymerization of actin. In contrast, rho kinase inhibitors, such as netarsudil, 
inhibit the function of ROCK and consequently result in relaxing smooth muscle-
like cells, dilation of ISP and ESVs, and depolymerization of actin. (JCT: 







LIMK, which in turn phosphorylates and inactivates cofilin, consequently 
inhibiting the depolymerization of actin.96 (Fig. 1-3) In contrast, Rho kinase 
inhibitors have been shown to relax the overall tone of the contractile cells in 
TM,54,97–100 loosen the connection between inner wall cells and the underlying 
JCT matrix,58,63 alter tissue architecture in such a way that expands the JCT 
region,54,61 and increase the permeability of cultured SC cell monolayers.54  
The therapeutic potential of Rho kinase inhibitors was initially 
demonstrated in preclinical studies using the Rho kinase inhibitor, Y-27632. In 
previous studies, Y-27632 was found to increase outflow facility in enucleated 
rabbit 100, porcine 54, bovine 58, monkey 63, and human 61 eyes. Increased outflow 
facility correlated positively with an increase in effective filtration areas, 
measured by percentage effective filtration length (PEFL),58,61,63 which was 
associated with an increased expansion in the JCT.54,61  Since the development 
of Y-27632, there have been 7 different selective Rho kinase inhibitors tested in 
human clinical trials in the U.S., Europe, and Japan. Among them, ripasudil was 
recently approved in Japan as a treatment for glaucoma and ocular 
hypertension.101 Netarsudil (a.k.a. AR-13324) is the first of a new class of Rho 
kinase inhibitors that also has inhibitory activity against the norepinephrine 
transporter (NET). In its Phase 2 clinical trial, once-daily dosing of netarsudil in 
patients with elevated IOP produced reductions in mean diurnal IOP ranging from 




Administration for the lowering of elevated intraocular pressure in patients with 
open-angle glaucoma or ocular hypertension.103,104 
 There have been several preclinical studies aimed at defining the 
mechanisms by which netarsudil reduces IOP. At the cellular level, netarsudil has 
been shown to induce cell shape changes, loss of actin stress fibers, loss of focal 
adhesions, and changes in extracellular matrix composition of TM cells.105 In 
monkeys, topical ocular application of netarsudil decreased IOP by 25% and 
increased outflow facility by 53%.106 In a rabbit model, application of netarsudil 
eye drops induced a significant reduction of episcleral venous pressure (EVP), 
which accounted for 42% of the measured IOP reduction.107 Increased outflow 
facility in mice by netarsudil was accompanied by decreased IOP, increased 
tracer distribution in TM tissues, plus increased lumen area of SC and intrascleral 
vessels. 108 In addition to its IOP lowering effects, netarsudil was also shown to 
promote the survival of retinal ganglion cells and axon regeneration after optic 
nerve injury.109 However, the effects of netarsudil on the tissues of the human 
trabecular outflow pathway have not been previously studied. 
 
1-6: Steroid-induced Ocular Hypertension 
Due to their broad-spectrum anti-inflammatory and immunosuppressive 
properties, glucocorticoids are one of the most commonly prescribed category of 




conditions. Approximately 1.2% of US population are prescribed oral 
glucocorticoids every year with a mean duration of usage to be over four 
years.110 However, the use of steroids can lead to significant ocular side effects. 
IOP elevation following steroid treatment was described for the first time in the 
1950s.111 Steroid-induced glaucoma is a form of secondary open angle glaucoma 
and clinically very similar to primary open angle glaucoma (POAG). In both 
clinical conditions, the elevated IOP is due to increased aqueous humor outflow 
resistance and is associated with morphologic and biochemical changes in the 
TM. Increased aqueous humor outflow resistance associated with increased 
deposition of extracellular matrix material (ECM)112–114 and altered ECM profile115 
was observed in POAG eyes. Although precise mechanism for IOP elevation 
after steroid intake is not very clear, steroids can induce similar changes in the 
TM ECM.116,117 Steroids are known to induce ocular hypertension when 
administered with topical, periocular, and even systemic or inhalational routes. 
IOP rise after steroid therapy occurs more frequently with topical administration 
than systemic administration.118 The IOP rise may occur with eye drops or 
ointment applied directly to the eye or over the skin of the eyelids.119,120 However, 
not all patients who receive steroid therapy develop steroid-induced ocular 
hypertension. Approximately 40% of the normal population have measurable IOP 
increase after 4-6 weeks of topical steroid treatment and are considered to be 




responders.121 Non-glaucomatous steroid responders are at higher risk for 
developing POAG compared to non-glaucomatous non-responders.122,123 In 
steroid-responsive patients, IOP elevation usually develops within the first few 
weeks of steroid administration. However, it can be elevated within an hour or 
many years after chronic steroid use. After steroid treatment is discontinued, IOP 
usually normalizes within 1 to 4 weeks. In about 3% of steroid responders , 
particularly when there is a family history of glaucoma and/or chronic use of 
steroid (at least 4 years), the ocular hypertensive response has been shown to 
be irreversible.124,125 For these patients, anti-glaucoma medications or surgery 
may become necessary. The duration of steroid therapy also appears to 
influence the reversibility of the IOP elevation.126 Despite their side effects, 
steroids remain the mainstay of therapy for inflammatory and immune mediated 
diseases and their usage may be necessary for patients with life-threatening 
cases, such as kidney inflammation, or vision-impairing cases, such as macular 
edema and uveitis. Therefore, although in most cases the steroid-induced ocular 
hypertension is reversible, the cessation of steroid treatment may not be practical 
for some patients. Unless the development of nonsteroidal anti-inflammatory 
therapies will provide effective alternatives to steroids, it is still necessary for us 
to better understand the mechanisms involved in steroid-induced ocular 




To investigate the mechanisms of steroid-induced ocular hypertension, 
various steroid-induced ocular hypertensive animal models have been developed 
in rabbits,127,128 cats,129 dogs,130 bovine,131 sheep,132 non-human primates,133 
rats,134,135 and mice136–138 models. These models confirmed the steroid-induced 
functional and morphological changes in the TM.135,137–145 
 
1-7: Thesis objectives 
The goal of this study is to thoroughly analyze hydrodynamics by evaluating 
changes in EFA and correlated morphological changes at multiple locations 
along the trabecular outflow pathway when a change in outflow facility or IOP is 
induced, both ex vivo and in vivo. By labeling outflow pattern in two different 
experimental conditions, either decreasing outflow resistance (by increasing 
outflow facility) or increasing outflow resistance (by increasing IOP) using an ex 
vivo perfusion model with normal human eyes or an ocular hypertensive mouse 
model, we analyzed the PEFL at multiple locations along the trabecular outflow 
pathway and guided by the PEFL changes, detailed morphological comparison 
was performed to investigate possible structural changes that may be 






Aim 1: To determine whether elevated outflow facility will be associated with an 
increased effective filtration area by using outflow agonist netarsudil. 
Netarsudil has rho kinase inhibitor function to target the trabecular pathway, 
and has been shown in clinical trials to be a promising next generation glaucoma 
medication. To explore the mechanisms of netarsudil-induced increase in outflow 
facility (resistance), the EFA and associated morphological changes were 
investigated in human donor eyes, using an ex vivo eye perfusion system. 
Fluorescent tracers were used as a guide to detect important hydrodynamic and 
morphological changes at multiple locations along the trabecular pathway using 
an imaging method that combines confocal, light, and electron microscopy.  
 
Aim 2: To determine whether there is an inverse relationship between effective 
filtration area and IOP in the steroid-induced ocular hypertensive mouse model. 
 To further explore the mechanisms of steroid-induced ocular hypertension, 
we investigate the relationship between the EFA and IOP and the hydrodynamic 
and morphological changes responsible for elevated IOP, using a chronic 
steroid-induced ocular hypertensive mouse model. We studied the steroid-
induced changes in EFA in vivo by labeling outflow patterns with anterior-
chamber-injected tracers. Guided by the distribution of tracers in TM, we 




imaging methods and immunohistochemistry, to investigate the possible 







CHAPTER TWO: Netarsudil Increases Outflow Facility in Human Eyes 
through Multiple Mechanisms 
 
2-1: Introduction 
Data from this study were published (Ren R, Li G, Dong Le T, Kopczynski 
C, Stamer WD, Gong H. “Netarsudil Increases Outflow Facility in Human Eyes 
through Multiple Mechanisms.” Investigative Ophthalmology & Visual Science 
2016; 57(14):6197-6209). Netarsudil is a new class of glaucoma medication that 
has dual functions as Rho kinase inhibitor and Norepinephrine transporter 
inhibitor. Before the final approval by Food and Drug Administration, netarsudil 
showed significant IOP reduction effects in clinical trials.102,146,147 However, the 
effects of netarsudil on hydrodynamics and morphology of outflow pathway, as 
well as detailed mechanisms for netarsudil to reduce IOP remain unclear. In the 
previous studies on another Rho kinase inhibitor, Y27632, increased outflow 
facility was found in treated bovine 58, monkey 63, and human 61 eyes with ex vivo 
perfusion. Netarsudil was also found to increase tonographic outflow facility in 
normotensive monkey eyes.106 Moreover, in the previous studies with Y27632, 
increased outflow facility was correlated positively with an increase in percentage 
effective filtration length (PEFL) at inner wall,58,61,63 which was associated with an 
increased expansion in the JCT.54,61 According to the Rho kinase signaling 
pathway, its Rho kinase inhibitor function suggests that netarsudil may relax the 




inner wall cells and the underlying JCT matrix,58,63. This would alter the TM tissue 
architecture in such a way that expands the JCT region,54,61 and increase the 
permeability of cultured SC cell monolayers.54 Similar to these findings, 
netarsudil was also shown to induce cell shape changes, loss of actin stress 
fibers, loss of focal adhesions, and changes in extracellular matrix composition of 
TM cells.105 A recent study showed that structures along trabecular outflow 
pathway, both proximal to SC (TM) and distal to SC (SC and intrascleral plexus), 
may respond to netarsudil treatment in living mouse eyes.108 In addition, another 
study also showed that besides IOP reduction, netarsudil reduced episcleral 
venous pressure in rabbit eyes.107 Altogether, these previous data suggest that 
netarsudil may increase outflow facility by interact with the structures along 
trabecular outflow pathway, both proximal to SC and distal to SC. In this current 
study, we perfused human donor eyes with or without netarsudil, with fluorescent 
tracers to label the outflow pattern. A recently developed global imaging 
technique56 was then utilized and combined with confocal imaging to analyze 
netarsudil-induced hydrodynamic changes at multiple locations along the 
trabecular outflow pathway. Guided by the tracer distribution, the detailed 
morphological comparison was performed between high tracer and low tracer 
regions of the trabecular outflow tissue. The goal of this study is to test our 
hypothesis that an increase in outflow facility by netarsudil-M1, the active 




trabecular outflow pathway that produce an increase in percentage effective 
filtration length (PEFL) in the TM, IW of SC, and ESVs of human eyes. 
 
2-2: Materials and Methods 
Materials 
Five pairs of enucleated human eyes from anonymous donors were 
obtained from the Miracles in Sight Eye Bank (Winston-Salem, NC). The mean 
donor age was 62 years (range 32-74). The mean postmortem time to the 
beginning of perfusion was 19 hours (range 7.5–28). There was no known history 
of ocular disease or surgery in four pairs of eyes; however, one pair of eyes 
presented with an intraocular lens (IOL). Each eye was examined under a 
dissecting microscope. Four of five pairs of eyes were confirmed to be grossly 
healthy, and one pair of eyes (without IOL) showed early signs of macular 
degeneration. 
The perfusate was Dulbecco’s phosphate-buffered saline (pH 7.3; GIBCO) 
containing 5.5 mM D-glucose (collectively referred to as GPBS). FluoSpheres® 
Carboxylate-Modified Microspheres (Ex/Em: 505/515, 200 nm in size, Molecular 
Probes, Eugene, OR) at 0.002% vol/vol concentration were used to visualize 
aqueous humor outflow patterns. The specific sizes and concentration of 
fluorescent microspheres were chosen based on a previous study that showed 
negligible obstruction of aqueous outflow through the TM. 148 Netarsudil-M1 (10 




kept at -20°C. Netarsudil-M1 working solution was diluted in GPBS to a final 
0.3µM concentration immediately before perfusion.  
Methods 
Ocular Perfusion 
The perfusion procedure was described in detail in our previous work. 60 
All eyes were initially perfused with GPBS at 15 mm Hg to establish a stable 
baseline facility for 30 minutes. Perfusion was halted and anterior chamber fluid 
from one eye of each pair was exchanged with 5 mL of 0.3µM netarsudil-M1 with 
0.42mM DMSO in GPBS, while its contralateral eye was exchanged with 0.42mM 
DMSO in GPBS. Perfusion was restarted with netarsudil-M1 and continued for 3 
hours. To label outflow hydrodynamics, perfusion was stopped and anterior 
chamber fluid from both eyes was exchanged for 5 mL of GPBS containing 
fluorescent microspheres. Perfusion was restarted and both eyes were perfused 
with a fixed volume (150 µl) of the microsphere solution. Perfusion was again 
stopped and anterior chamber fluid from both eyes was exchanged with a 
modified Karnovsky’s fixative (2.5% glutaraldehyde and 2% paraformaldehyde, 
pH 7.3), and the eyes were perfusion-fixed at 15 mm Hg for 30 min. After 
perfusion was completed, a small cut was made along the equator, and each eye 
was immersed in the same fixative overnight. All eyes were then stored in 
phosphate-buffered saline (PBS) at 4oC until further processing. All following 
outflow pattern and morphological analyses were performed on the eyes after the 




Duke University and shipped to Boston University School of Medicine for further 
processing, imaging and analysis. 
 
Global Imaging 
All perfused eyes were processed to image the active outflow areas along 
the entire outflow pathway as previously described. 56 Eyes were first dissected 
along the equator into anterior and posterior segments. Anterior segments of all 
eyes were further processed by removing the iris, ciliary body, cornea (with a 10 
mm trephine), vitreous, and excess conjunctiva. To visualize active outflow 
areas, the remaining anterior segments were then imaged globally with blue LED 
epi-illumination on both their scleral (anterior view) and TM (posterior view) 
surfaces with a fixed exposure time of 5 seconds (Fig. 2-1A) using a 300mm lens 
on a 4000MP VersaDock imaging system (Bio-Rad Laboratories, Hercules, CA) 
operated by Quantity One (Bio-Rad Laboratories, Hercules, CA).  
 
Analysis of Percent Effective Filtration length (PEFL) from Global Images 
Acquired global images were analyzed to quantify areas of active outflow 
in the episcleral veins (ESVs) and TM. To avoid including the auto-fluorescent 
sclera as a false positive signal, each global image underwent background 
subtraction using a fixed value (60 pixels) in ImageJ (NIH, Bethesda, MD). 
Images were then digitally separated into 16 “wedges” (Fig. 2-1B). We termed 



















Figure 2-1. Global Image Analysis.  
A: Global images of anterior segments of perfused human eyes showing the 
outflow tracer patterns in the posterior [trabecular meshwork (TM)] and anterior 
[episcleral vein (ESV)] views. (N: nasal; T: temporal; S: superior; I: inferior). B: 
Each global image was digitally separated into 16 wedges after background 
subtraction. C- D: Percentage effective filtration length (PEFL) was calculated in 
each wedge. The green lines represent total filtration length (TFL), and the red 
lines represent total scleral length (TSL). PEFL = ΣTFL/ΣTSL. In the anterior 
view global image (C), ESV PEFL of each wedge was calculated by averaging 
the PEFL measured at three locations: inner, middle and outer. In the posterior 





tracers as the effective filtration area, which was represented by percent effective 
filtration length (PEFL). To calculate PEFL, global images of the TM and scleral 
surfaces were measured for the total scleral length (TSL) and total tracer-labeled 
length (TFL) for each wedge. Three distinct measurements (inner, middle, outer) 
for TSL and TFL were taken from global images of the scleral surface (Fig. 2-1C) 
and the PEFL was calculated as PEFL = [(ΣTFL/ΣTSL)inner + (ΣTFL/ΣTSL)middle 
+(ΣTFL/ΣTSL)outer]/3 in each digital wedge. The overall ESV PEFL was 
calculated by determining the mean PEFL of all 16 wedges. For determining TM 
PEFL, only one measurement was necessary to obtain both TSL and TFL (Fig. 
2-1D).  TM PEFL was calculated as TM PEFL = ΣTFL/ΣTSL.  The ESV/TM PEFL 
of each group is the average of five eyes. All measurements in this study were 
done in a masked fashion. 
 
Confocal Microscopy 
Following global imaging and analysis, anterior segments were further 
dissected into 16 radial wedges, from which frontal sections were cut along a 
plane tangential to the corneoscleral limbus and perpendicular to the ocular 
surface 58,149 to bisect SC and TM. All the frontal dissections were performed by 
an experienced investigator (HG). Each frontal section was permeabilized with 
0.01% (v/v) Triton X-100 (Sigma Aldrich, St. Louis, MO) and counter-stained with 
either DAPI (Sigma Aldrich, St. Louis, MO) or TO-PRO 3 Iodide (Life 




using an Axiovert LSM 700 (Carl Zeiss, Germany) with a 20x objective. Images 
were taken in all sections containing SC, so that the distribution of the tracer 
along the inner wall and the TM could be properly analyzed. A minimum of 75 
images was taken for each eye.  
 
Analysis of PEFL from Confocal Images 
Similar to the ESV PEFL and TM PEFL calculations from global images, 
the total length (TL) of the inner wall of SC and fluorescent-decorated length (FL) 
of the inner wall in each image were measured using ZEN 2010 (Carl Zeiss, 
Germany), and the average percent effective filtration length (IW PEFL = 
ΣFL/ΣTLx100%) in each eye was calculated (Fig. 2-2A).  
 
TM Thickness Measurements 
For the TM thickness measurement, the TM were designated as three 
regions based on the following criteria:  1) high tracer regions: IW PEFL>50%/ 
per 200µm, 2) medium tracer regions: IW PEFL <50% but either IW EFL or the 
tracer labeled TM >5% per 200µm and 3) low tracer regions: both IW PEFL and 
the tracer labeled TM < 5%/ per 200µm. TM thickness (the length from the 
innermost uveoscleral beams to the inner wall endothelium of SC) was measured 
for all confocal images with clearly visible SC and innermost uveoscleral beams 
at every 200µm of IW length (Fig. 2-2B).  The average thickness of TM in high 




TM thickness [TM thickness overall = TM thickness high tracer region x IW PEFL + TM 
thickness low tracer region x (1-IW PEFL)] was then calculated and analyzed. The 
criterion for TM thickness measurement was different from the PEFL 
measurement above, where only the inner wall of SC needed to be clearly 
visible, while both inner wall of SC and the innermost uveoscleral beams needed 
to be clearly visible for the TM thickness measurement. Therefore, the total 
length measured for the TM thickness was shorter than the total length measured 
for the IW PEFL. But at least 22mm of total IW length of TM was measured in 
each eye. 
 
Light Microscopy for General Morphology 
Unlike the high/medium/low tracer regions for TM thickness analysis in 
confocal images, which were determined by their local tracer distribution, the 
high/low tracer sections processed for light microscope images were selected 
based on the average IW PEFL of each wedge, and two frontal sections with the 
highest tracer distribution and two frontal sections with the lowest tracer 
distribution were further processed for light microscopy. All chosen frontal 
sections were stained with 2% osmium tetroxide and 1.5% potassium 
ferrocyanide for 2 hours, en bloc stained with 2% uranyl acetate for 90 min, 
dehydrated in an ascending series of ethanol and propylene oxide, and 










Figure 2-2. Confocal Image Analysis.  
A: Inner wall percentage effective filtration length (IW PEFL) measurement. The 
red lines represent effective filtration length (FL), and the yellow line represents 
total length (TL) of the inner wall of Schlemm’s canal (SC). The green represents 
the tracer distribution, and the blue represents the nuclei. The average IW PEFL 
in each perfused human eye was calculated as IW PEFL= ΣFL/ΣTL. B: 
Trabecular meshwork (TM) thickness measurement. The red line represents the 
thickness of TM from the innermost uveoscleral beam to the inner wall 
endothelium of SC, which was measured at every 200µm length of IW. Low 
tracer and high tracer regions were determined by the tracer distribution shown in 






1% Toluidine Blue (Fisher Scientific, Pittsburgh, PA). Light microscope images 
were taken using a 20x objective along the inner wall of SC. 
 
Episcleral Vessel Size Measurements 
Frontal sections (2 µm) from radial wedges containing high tracer in both 
the IW and the ESVs from all ten eyes were processed for light microscopy and 
imaged. The morphology of the episcleral blood vessels was examined and 
episcleral arteries were excluded based on their typical circular appearance 
enclosed by muscular walls (Fig. 2-3A). The remainder of the ESVs were 
measured and analyzed. The size of each ESV was measured by cross-section 
area using ImageJ (Fig. 2-3A). The major and minor axes, dubbed the x- and y-
axes, were also measured. Veins with aspect ratios (x:y) ≥5.0 were also removed 
from the data pool due to the possibility that they were oblique sections, not 
radial. The measurements of twenty veins were then selected from each of the 
ten eyes via simple random sampling (n=100 each for control and treated) for 
further analysis.  
 
Electron Microscopy 
Among the sections processed for light microscopy, one high tracer frontal 
section and one low tracer frontal section from each eye was randomly selected 
for further processing for electron microscopy. Ultrathin sections (80 nm) were 




Tokyo, Japan). Electron microscope images were taken along the inner wall of 
SC in all selected sections. 
 
 
JCT Thickness Measurements 
JCT area was measured in 3000x electron microscopic images by 
selecting the area from the basal side of the IW endothelium to the empty space 
adjacent to the outermost corneoscleral beams and measuring the cross-section 
area using ImageJ (Fig. 2-3B). JCT length was also measured in ImageJ. 
Average JCT thickness (ΣJCT area / ΣJCT length) was calculated for both high 
and low tracer sections of each eye as well as the mean overall JCT thickness 
[JCT thickness overall = JCT thickness high tracer region x PEFL + JCT thickness low tracer 
region x (1-PEFL)]. 
 
Statistical Analysis 
Student’s t-test, linear regression analysis and the linear mixed-effects 
model for repeated measures were applied with a required significance level of p 










Figure 2-3. Light and Electron Microscopic Analyses.  
A: Methods of episcleral vein (ESV) measurements. Cross-sections of ESVs 
(white arrows) and episcleral arteries (black arrows) were shown in a light 
microscopic image. The cross sectional areas of ESVs were measured and 
calculated by ImageJ. The perimeter of the area measured is shown in green in 
the inset, which is a zoomed-in view of the squared area. B: Methods of 
juxtacanalicular connective tissue (JCT) thickness measurement. JCT area (red) 
and JCT length (yellow) were measured in an electron microscopic image and 
the average JCT thickness (ΣJCT area / ΣJCT length) was then calculated 









While clamping pressure at 15 mm Hg, outflow of both netarsudil-M1-
treated and control groups (n=5 each) was continually measured and outflow 
facility was calculated at baseline and at 30min, 2hr, and 3hr following drug or 
vehicle application (Table 2-1, Fig. 2-4A). Outflow facility increased over time in 
the netarsudil-M1-treated group, while remaining unchanged in the control group. 
Outflow facility of the netarsudil-M1 group versus the GPBS group was 0.28±0.05 
vs. 0.21±0.03 µl/min/mm Hg (p=0.08, one tailed, paired t-test) at baseline, 
0.34±0.05 vs. 0.20±0.03 (p=0.005) at 30min after perfusion, 0.40±0.04 vs. 
0.21±0.03 (p=0.0002) at 2hr after perfusion, and 0.43±0.05 vs. 0.21±0.04 
(p=0.0002) at 3hr after perfusion. When compared to its own baseline, the 
netarsudil-M1 group had shown a significant increase after 30min perfusion (p= 
0.046 at 30min, 0.004 at 2hr, and 0.0006 at 3hr, one tailed, paired t-test). In 
contrast, the GPBS group had no change in outflow facility over the entire 3hr-
perfusion when compared to its own baseline (p= 0.35 at 30min, 0.42 at 2hr, and 
0.45 at 3hr). 
Percent change in outflow facility in netarsudil-M1 treated eyes increased 
in a perfusion time-dependent manner, while remaining unchanged in control 
eyes (Fig. 2-4B). The percent change in outflow facility of the netarsudil-M1 




paired t-test) at 30min, 50.13±14.64% vs. -3.35±7.24% (p=0.02) at 2hr and 
59.70±13.65% vs. -1.70±10.34% (p=0.02) at 3hr.  
Outflow facility change from baseline at the last time point (3 hr) was 
further analyzed by using the linear mixed-effects model for repeated measures 
(MMRM). The analysis included the fixed categorical effects of treatment, time 
point, treatment-by-time point interaction, and the covariate of baseline outflow 
facility measurement, with the baseline outflow facility measurement-by-time 
point interaction adjusted in the model. The restricted maximum likelihood 
(REML) method with a Compound Symmetry (CS) covariance structure shared 
across treatment groups was used to model the within-patient errors. The 
Kenward-Roger method was used to estimate denominator degrees of freedom 
and adjust standard errors (SEs). The least square (LS) means of the control and 
treatment group were -0.02 and 0.12, respectively. At the 3 hr time point, the 
difference in LS mean change from baseline between the control and treatment 
groups (-0.14) was statistically significant (p<0.001, t=-9.47 and DF=18.5). This 
increasing value in outflow facility change from baseline at the last time point (3 
hr) indicates a positive drug effect. 
 
Percent Effective Filtration Length (PEFL) 
PEFL was calculated for ESVs (anterior view) and TM (posterior view) 
using global imaging of the anterior segments and for the IW of SC by using 




Table 2-1. Outflow facility change over time.  
Pair # of 
Eyes 
Perfusate 
Outflow Facility (µl/min/mm Hg) 
baseline 30min 2h 3h 
1 
GPBS 0.159 0.153 0.150 0.137 
netarsudil-M1 0.276 0.265 0.356 0.388 
2 
GPBS 0.235 0.272 0.253 0.297 
netarsudil-M1 0.459 0.486 0.505 0.566 
3 
GPBS 0.242 0.231 0.285 0.289 
netarsudil-M1 0.253 0.289 0.432 0.454 
4 
GPBS 0.280 0.226 0.240 0.240 
netarsudil-M1 0.290 0.416 0.430 0.450 
5 
GPBS 0.126 0.127 0.098 0.093 










Figure 2-4. Outflow Facility.  
A: Netarsudil-M1 treatment increased outflow facility over time. Netarsudil-M1 
treated eyes showed significantly increased outflow facility at all time points 
compared to the controls (##: p<0.01). There was also a significant increase 
when compared to its own baseline (*: p<0.05; **: p<0.01). B: The percentage 
change in outflow facility in netarsudil-M1 treated eyes also showed a significant 
increase when compared to the controls after 2hrs and 3hrs of perfusion (*: 






were segmental, having both high and low tracer regions. PEFL at ESVs was 
45.64±3.61% in the netarsudil-M1 group, which was significantly greater when 
compared to the control group ESV PEFL of 22.58±1.50% (p=0.007, two tailed, 
paired t-test) (Fig. 2-5A). Although TM PEFL increased in 4 out of 5 eyes after 
netarsudil-M1 treatment, the difference in mean TM PEFL compared to controls 
did not reach statistical significance (83.05±5.55% vs. 72.19±5.72%, p=0.28).  
PEFL at the IW was 35.27±5.14% in the netarsudil-M1 group, which was 
significantly greater when compared to the control group IW PEFL of 
21.26±2.84% (p=0.007). However, while PEFL at the ESVs and IW was similar to 
each other in controls (p=0.63), the increase in PEFL at ESVs was significantly 
greater compared to the increase in PEFL at the IW in netarsudil-M1 treated 
eyes (p=0.03). Furthermore, there is a significant positive correlation between 
ESV PEFL and the percent change in outflow facility (R2=0.58, p=0.01) (Fig. 2-
5B). IW PEFL, on the other hand, did not correlate to the percent change in 
outflow facility (R2=0.28, p=0.11). Altogether, our findings suggest that trabecular 
outflow was modulated mostly in TM and netarsudil-M1 caused a further 
decrease of outflow resistance in trabecular outflow tissue distal to SC. Outflow 
facility was only significantly correlated with ESV PEFL but not with IW PEFL. 
 
Trabecular Meshwork Thickness 
TM regions were designated as low tracer (local PEFL and local tracer 









Figure 2-5. Episcleral Vein Percentage Effective Filtration Length (ESV 
PEFL) and Inner Wall (IW) PEFL.  
A: Netarsudil-M1 treatment induced a significant increase in both ESV and IW 
PEFL when compared to controls. While ESV PEFL and IW PEFL remained 
similar to each other in control eyes, ESV PEFL in treated eyes showed a 
significant increase beyond the increase observed for the IW PEFL (*: p<0.05; **: 
p<0.01) (n=5).  B: ESV PEFL was found to have a positive correlation with 
percent change in outflow facility (R2 = 0.58; p = 0.01; solid circles: control eyes; 
solid triangles: netarsudil-M1-treated eyes). ①
  
                                                        
① More data points will be needed to confirm this correlation, as well as the possibility that treated and 




tracer presence in TM greater than 5% but local PEFL less than 50% per 200µm 
IW) or high tracer (local PEFL greater than 50% per 200µm IW) regions (Fig. 2-
6A). In the control eyes, the TM thickness was 93.52±9.22 µm in low tracer 
regions, 103.71±4.77 µm in medium tracer regions, and 115.20±7.48 µm in high 
tracer regions. The increase in tracer presence was associated with an increase 
in the average TM thickness and TM thickness in high tracer regions was 
significantly greater compared to that in low tracer regions (p=0.02, two tailed, 
paired T-test) (Fig. 2-6B).  However, after netarsudil-M1 treatment, the difference 
in TM thickness between low tracer and high tracer regions was not significant 
(p=0.32). After careful comparison, we found that TM thickness was similar 
between the treated and control groups in medium tracer regions (105.25±6.37 
vs. 103.71±4.77 µm, p=0.80) and high tracer regions (113.86 ± 5.92 vs. 
115.20±7.48 µm p=0.77); however, in low tracer regions, the mean TM thickness 
was increased in the treated group compared to the control group (101.69±13.08 
vs. 93.52±9.22 µm). Although this increase was not statistically significant 
(p=0.60), it may contribute to the loss of statistical significance between the low 
and high tracer regions after netarsudil-M1 treatment. The overall TM thickness 
showed no significant increase after netarsudil-M1 treatment (from 97.61±8.82 




















Figure 2-6. Trabecular Meshwork (TM) Thickness.  
A: Representative confocal images of TM and Schlemm’s canal (SC) are shown 
in low tracer, medium tracer, and high tracer regions of control (GPBS) and 
netarsudil-M1 treated eyes respectively. The green represents the distribution of 
tracer. The blue represents the nuclei. B: TM thickness in high tracer regions 
was significantly higher when compared to low tracer regions in control eyes. 
However, there was no significant difference between low tracer and high tracer 
regions in netarsudil-M1 treated eyes (*: p<0.05) (n=5). C: The overall TM 
thickness was not significantly different between the netarsudil-M1 treated and 
control eyes. D: Representative light microscopic images show the morphology 
in high tracer vs. low tracer regions of control and treated eyes. Double arrows 
represent TM thickness. TM structure was more expanded in high tracer regions 
when compared to low tracer regions in control eyes. More expanded TM was 







Our morphologic observation of TM thickness by light microscopy was 
consistent with our confocal results. The TM was more expanded in the high 
tracer regions compared to low tracer regions in control eyes, and an expansion 
of the TM was observed in the low tracer region of netarsudil-M1 treated eyes 
(Fig. 2-6D). In addition, examination of ESV morphology in high tracer regions 
revealed a significantly larger average cross-sectional area of ESVs in netarsudil-
M1-treated eyes compared to control eyes (3735±405 vs. 2231±217 µm2, 
p=0.001, two tailed, unpaired t-test) (Fig. 2-7A). The distribution of ESV cross-
sectional area showed a shift to the right (larger size) (Fig. 2-7B), suggesting 




Average JCT thickness in IW high tracer regions of control eyes 
(11.22±1.00 µm) was greater when compared to that in low tracer regions 
(6.93±0.87 µm). This difference in JCT thickness approached but did not reach 
statistical significance (p=0.08, two tailed, paired t-test) (Fig. 2-8). No significant 
difference in JCT thickness was found between high tracer regions and low 
tracer regions in netarsudil-M1-treated eyes (p=0.35). In netarsudil-M1-treated 
eyes, mean JCT thickness in high tracer regions was similar to control eyes 
(11.47±0.93 µm, p=0.84), while mean JCT thickness in low tracer regions of 









Figure 2-7. Size of Episcleral Veins (ESVs).  
A: Netarsudil-M1 treatment significantly increased the average cross-sectional 
area of ESVs compared to GPBS control (**: p<0.01) (n=100). B: In treated eyes, 


















Figure 2-8. Juxtacanalicular Connective Tissue (JCT) Thickness.  
A: Representative electron microscope images of JCT from low tracer and high 
tracer regions of GPBS control (left column) and netarsudil-M1 treated (right 
column) eyes. Bottom row presents a larger view of the squared region in middle 
row. The presence of tracers is indicated with black arrows. B: A more expanded 
JCT was found in the high tracer regions than low tracer regions in control eyes. 
Netarsudil-M1 treatment induced a significant increase in the JCT thickness in 
low tracer regions compared to low tracer regions in control eyes (*: p<0.05) 
(n=5). C: The overall JCT thickness was increased in netarsudil-M1 treated eyes 











Figure 2-9. Characteristic morphologies in high tracer regions in both 
netarsudil-M1-treated and untreated eyes.  
Black arrows are indicating the presence of tracer beads. A: The detachment of 
an IW cell; B: The merging of two giant vacuoles (GVs); C: IW cells engulfing 
tracer; D: TM cells (arrowheads) engulfing tracers and flowing into the JCT 
region; E: Extra-cellular matrix and tracer beads in a GV; F: A cell (arrowhead) in 






tracer region of controls (10.41±0.37 vs. 6.93±0.87 µm, p=0.02) (Fig. 2-8B). The 
mean overall JCT thickness was significantly increased (p=0.02) after netarsudil- 
M1 treatment compared to controls (10.85±0.43 µm vs. 7.73±0.62 µm) (Fig. 2-
8C). 
Except for the change in JCT thickness in low tracer regions of netarsudil-
M1-treated eyes, there were no other obvious morphological changes found in 
high and low tracer regions when comparing treated and control eyes. However, 
certain characteristics in high tracer regions seem to be observed more often in 
treated eyes than in controls. One example is the detachment of inner wall cells 
from their basement membrane (Fig. 2-9A). Although this is not a common 
phenomenon, there was 249 µm (11.15%) of detached IW observed in the 2233 
µm total IW length analyzed in the high tracer regions of treated eyes, while this 
ratio was 177 µm/ 2252 µm (7.86%) in the high tracer regions of control eyes. In 
the low tracer regions, this ratio was 49 µm /1712 µm in treated and 9 µm/ 2147 
µm in control eyes. Therefore, although observed in high tracer regions of both 
treated and control eyes, this detachment seems present more often in both high 
and low tracer regions of treated eyes. Six such morphological changes 
observed more frequently in treated eyes are shown in Figure 9. Besides the 
detachment of IW cells, there was a greater incidence in treated eyes of joint 
giant vacuoles (several giant vacuoles merging together, Fig. 2-9B), IW cells 




matrix present within giant vacuoles (Fig. 2-9E), and cells in the giant vacuoles 
(Fig. 2-9F).  
 
2-4: Discussion 
In this study, we investigated the effects of netarsudil-M1, a dual inhibitor 
for Rho kinase and NET, on aqueous humor outflow facility, outflow 
hydrodynamics, and morphology after a 3-hour perfusion in enucleated human 
eyes. We found that, similar to a previous study of aqueous humor dynamics in 
monkey eyes106, netarsudil-M1 acutely increased outflow facility in human eyes. 
The percent change in outflow facility was time-dependent. By carefully 
evaluating hydrodynamic and morphological changes, we found that netarsudil-
M1 induced an increase in both JCT thickness and cross-sectional areas of 
ESVs, both of which correlated with a significant increase in the PEFL at the 
inner wall of SC and in the ESVs. Additionally, we found a significantly larger 
increase in the PEFL in ESVs compared to the IW, and PEFL in the ESVs was 
positively correlated to the percent increase in outflow facility. Our results support 
our hypothesis that an increase in outflow facility by netarsudil-M1, the active 
metabolite of netarsudil, is associated with morphological changes along the 
trabecular outflow pathway that produce an increase in the active filtration areas 
in the IW of SC and ESVs of human eyes.  
Compared to a previous study, in which the effects of the Rho kinase 




after perfusion in enucleated human eyes were investigated, 61 a similar increase 
in the percent change of outflow facility was induced by netarsudil-M1 
(24.66%±12.57% for 30 min and 59.70%±13.65% for 3hr) as by Y-27632 
(29.0±10.6% for 30 min and 60.6±16.9% for 3hr). However, the concentration of 
netarsudil-M1 (0.3µM) used in this study was 167-fold lower than the working 
concentration of Y-27632 (50µM) in the previous study, signifying that netarsudil-
M1 is more potent for increasing outflow facility and reducing IOP.  
Aqueous outflow is segmental along the conventional outflow pathway in 
non-human 57–59,62and human eyes 56,61,150–152.  Previous studies demonstrated 
that the active filtration area, represented by PEFL, was a critical parameter for 
indicating changes in outflow facility 57–62 and IOP 65. In the previous study with 
Y-27632, in which PEFL was measured only at the IW but not at ESV, Y-27632-
treated eyes showed an increase in IW PEFL as well as a positive correlation 
between IW PEFL and percent change in outflow facility. However, in our current 
study, after 3hr netarsudil-M1 perfusion IW PEFL increased 14.0% when 
compared to the controls (35.27±5.14% vs. 21.26±2.84%). Although this increase 
was significant, it was smaller than the 17.4% increase (63.6±5.8 vs. 46.2±4.8) 
caused by perfusion withY-27632 in the previous study. Additionally, we did not 
find a significant positive correlation between the IW PEFL and percent change in 
outflow facility as that reported in the previous studies with Y-27632 in bovine 58, 
monkey 59 and human eyes. 61 We would expect that the smaller increase in IW 




However, the total increase in outflow facility was similar between netarsudil-M1-
treated and Y-27632-treated eyes. This data led us to hypothesize that similar 
increase in outflow facility induced by netarsudil-M1 as by Y-27632 may be due 
to an additional increase in PEFL distal to the inner wall of SC in the conventional 
outflow pathway. To address this possibility, we compared the active filtration 
areas (represented by PEFL) in three locations in the trabecular outflow pathway: 
TM, IW, and ESV, by combining confocal microscopy with a recently developed 
global imaging technique. 56 To the best of our knowledge, it is the first time this 
approach was used to investigate the drug’s effect along trabecular outflow 
pathway in human eyes. We found that netarsudil-M1 significantly increased 
PEFL in both IW of SC and ESVs, and the ESV PEFL was significantly larger 
than the IW PEFL compared to similar PEFLs between the IW and in ESVs in 
control eyes.  Although the increase in IW PEFL did not show a positive 
correlation with the percent change in outflow facility, a significant positive 
correlation was found for the increase in ESV PEFL. These data supported our 
hypothesis that netarsudil-M1 induced an additional increase in PEFL distal to 
SC, which contributed to the increase in outflow facility.  
The mechanisms by which netarsudil may cause decreased resistance in 
the distal outflow pathway cannot be fully explained by our data. Netarsudil has 
been reported to significantly reduce EVP in rabbits after topical application, 
which contributed substantially to the reduction of IOP. 107 An OCT study in living 




response to topical netarsudil treatment.108 Given that Rho kinase inhibitors can 
cause vasodilation 153,154, we hypothesized that netarsudil-M1-treated eyes may 
induce dilation of ESVs. Our histological findings support our hypothesis by 
showing that netarsudil-M1 significantly increased the size (cross-sectional area) 
of ESVs. This dilation of ESVs is consistent with the reduction in EVP seen in 
rabbits. According to our measurements, the majority (>55%) of ESVs in control 
eyes have a cross-sectional area of less than 2000 µm2.These data suggest that 
the size of the majority of ESVs is similar to that of venules, which are 15-50 µm 
in diameter 155 and estimated to have a cross-sectional area of 180-2000 µm2, if 
calculating based on their diameter. The size of venules is small enough to cause 
post-capillary resistance to blood flow. Venules can also respond to the 
application of vasoactive substances and result in changes in venular resistance 
156, which implies that they play a role in controlling blood flow. Although the 
resistance to aqueous outflow in this study should be much less when compared 
to resistance to blood flow due to the significantly lower viscosity that our 
perfusate has, it is possible for the ESVs to account for a portion of the 
resistance to the distal outflow. Our data show that there is a 67% increase in the 
mean cross-sectional area of individual veins after netarsudil treatment. 
According to Poiseuille’s Law, flow resistance would be the fourth power 
dependence upon the radius. Therefore, after netarsudil treatment, flow 
resistance caused by ESVs would be about one third of the original resistance. In 




smaller, more tortuous vessels of the intrascleral plexus (which could not be 
assessed in current study), and that netarsudil-induced dilation of these vessels 
reduced the resistance to aqueous outflow even more and thereby increased the 
total outflow facility. A recent study in normotensive human eyes showed that 
topical netarsudil lowered IOP via both increasing outflow facility and reducing 
EVP, indicating a combination of mechanisms that affect both the proximal and 
distal outflow pathways.157 In addition, in clinic, trabecular meshwork bypass 
procedures were shown unable to achieve the IOP decrease observed with 
trabeculectomy, 158–160 indicating TM is not the only location where outflow 
resistance generates. Therefore, although more investigation may need to be 
conducted to unveil the full picture of the role of netarsudil in regulation distal 
outflow resistance, our data provided novel evidence and one possible 
mechanism for distal outflow regulation, which has the potential to become a new 
target for glaucoma treatment. 
Although global imaging of the TM revealed that PEFL increased in 4 out 
of 5 of netarsudil-M1-treated eyes, this increase did not reach statistical 
significance when compared to controls. Global imaging also revealed that in 
both control and treated eyes, the PEFL at the TM (70-80%) was substantially 
larger than the PEFL at the IW (20-30%). This is consistent with the previous 
findings suggesting that the majority of outflow resistance is located in JCT and 
IW regions 7,43–45,  causing a significant decrease in active filtration area when 




Similar to our previous studies 56,61, we found a significantly greater TM 
thickness in high tracer regions than in low tracer regions in untreated control 
eyes. Morphologically, a looser or more expanded TM structure was observed in 
the high tracer regions suggesting the region with lower outflow resistance, while 
a more compacted TM structure was observed in low tracer regions indicative of 
regions with higher outflow resistance. Although overall TM thickness was 
increased by 8.42µm after netarsudil-M1-treatment, this increase did not reach 
statistical significance (p=0.47) due to a small N and variability between 
individuals. Netarsudil-M1 treatment did produce a statistically significant 
increase in overall JCT thickness of 3.13µm (p=0.02). 
Interestingly, we found that TM thickness in high/medium tracer regions 
after netarsudil-M1 treatment was similar to controls, and JCT thickness was also 
similar to controls in high tracer regions. In contrast, we found that JCT/TM 
thickness was increased in low tracer regions after netarsudil-M1 treatment. One 
possible explanation for this observation is that the TM/JCT thickness in high 
tracer regions is already expanded and thus less affected by drug treatment.  
The increase in IW PEFL induced by netarsudil-M1 treatment may result 
primarily from its ability to change the more compacted TM structure of low tracer 
regions to a looser or more expanded structure. When such morphological 
changes reach a threshold, previous low flow regions could become medium or 





Our study has provided evidence of hydrodynamic and morphological 
changes induced by netarsudil-M1 along the trabecular outflow pathway, which 
may be responsible for the measured increase in outflow facility. However, there 
were some limitations to this study due to the experiments being performed in 
enucleated eyes. Using enucleated eyes allowed us to functionally isolate the 
conventional outflow tract and perform detailed morphological evaluations post 
drug perfusion. Unlike in vivo conditions, however, this model cannot evaluate 
the impact of aqueous humor production, normal ciliary body tone, episcleral 
venous pressure or uveoscleral outflow which has recently been reported to 
increase with treatment of rho kinase inhibitor, Y27632, in monkey eyes. 161 
Since we were not able to evaluate netarsudil’s effects on aqueous humor 
production, its function as a NET inhibitor was not investigated in this study. In 
addition, since the episcleral venous pressure is zero in enucleated eyes 
compared to approximately 7 mm Hg in the in vivo condition 162, the 15 mm Hg 
pressure we used for perfusion produced a relatively higher pressure gradient 
across the TM than is typical for normotensive eyes. With these known 
limitations, we were only able to investigate a subset of the mechanisms through 
which netarsudil-M1 may increase outflow facility in human eyes. Further animal 
studies or clinical studies will be needed to investigate other potential effects of 
this drug. 
In summary, we found that the active metabolite of netarsudil, netarsudil-




active filtration in the trabecular outflow pathway. Morphological correlations with 
this increase include expansion of the TM/JCT and dilation of ESVs. A 
significantly larger increase in PEFL was found in ESVs than in the IW, 
suggesting netarsudil may reduce outflow resistance distal to the IW of SC, 
which needs to be confirmed with further in vivo study. It will be interesting to see 
the impact of these drug effects on the long-term function of the diseased 






CHAPTER THREE: Reduced Effective Filtration Area in the Trabecular 
Meshwork of Steroid-induced Ocular Hypertensive Mouse Eyes 
 
3-1: Introduction 
The perfusion studies using enucleated eyes allow us to perform detailed 
morphological examinations post-perfusion; however, this model also has known 
limitations as discussed previously. Therefore, it is necessary to also test the 
relationship between PEFL and IOP in vivo with animal models. The mouse can 
serve as an effective animal model for ocular hydrodynamic studies due to the 
similarity of its drainage pathway to that of humans.163–165 Our group previously 
demonstrated a negative correlation between the TM PEFL and IOP in a rodent 
SPARC (secreted protein, acidic and rich in cysteine) knock out model of ocular 
hypotension.65 Decreased collagen diameter in TM was found to be associated 
with increased TM PEFL in SPARC-null mouse. The goal of the current study is 
to determine whether an inverse relationship between the PEFL and IOP also 
exists in an ocular hypertensive model and to investigate what morphological 
changes are responsible for the reduction of EFA. We utilized a recently reported 
model that increases IOP by topical administration of dexamethasone.138,166 
Dexamethasone, a type of corticosteroid medicine, is widely used to treat eye 
inflammation caused by infections, injury, post-ocular surgeries or other 
conditions. One of its side-effects is to increase IOP and could induce glaucoma 




hypertension as a consequence of impaired aqueous humor outflow through the 
TM168,169  and may also change gene expression of TM cells.141 Since it may 
impair outflow via the TM, we hypothesize that dexamethasone will induce 
structural changes in the trabecular outflow pathway of administered mouse 
eyes, resulting in a decrease in the effective filtration area and thereby, an 




All experiments were completed in compliance with the ARVO Statement 
for the Use of Animals in Ophthalmic and Vision Research. Local Institutional 
Animal Care and Use Committee (IACUC) approval was obtained. Twenty-eight 
C57BL/6 mice (6-weeks-old) were purchased from Charles River Laboratories 
(Wilmington, MA). All mice were housed in the Animal Science Center of Boston 
University Medical Campus, with a 12-hour light/12-hour dark cycle and access 
to food and water ad libitum. Upon arrival, mice were examined to confirm a 
normal appearance, i.e. free of any signs of ocular disease, and allowed to 
acclimatize for at least three days before the measurement for baseline IOP and 
the administration of dexamethasone or saline. 
 




Twenty-eight mice were randomly divided into two groups: saline-treated 
control group and dexamethasone-treated group (n=14 each). Each group 
includes both males and females. A small eye drop (∼10 μl) of either 0.1% 
dexamethasone phosphate (Henry Schein Inc., Melville, NY) or sterile saline 
(both containing 9.4mg/ml hydroxyethyl cellulose) was topically applied to both 
eyes of each mouse twice per day for 5 weeks. The initial daily dose was given 
between 9 am and 11 am, and the second dose between 5 pm and 7 pm. To 
ensure the effective penetration of the eye drops into the anterior chamber, mice 
were exposed to 2.5% isoflurane and 0.5L/min oxygen during the eye drop 
administration and recovered naturally (for ~30 seconds) in a separate cage 
before being put back into their cages.  
 
IOP Measurement 
For all mice used in this study, after initial baseline IOP measurement, IOP 
was measured weekly between 9 am and 11 am using a rodent rebound 
tonometer (Icare® TONOLAB; Icare, Vantaa, Finland). Mice were initially 
anesthetized with 5% isoflurane plus 0.5L/min oxygen in an anesthesia chamber 
for ~40 seconds and then attached to a nose cone with constant flow with 2.5% 
isoflurane plus 0.5L/min oxygen for IOP measurements. Each eye was measured 
for three readings (each reading was averaged from 6 independent 
measurements by the tonometer) and the median was taken as the final IOP. 




minutes, around 2 minutes and 10 seconds in most cases); longer isoflurane 
exposure rapidly decreased IOP, especially in dexamethasone-treated mice.170  
 
Microbead Injection 
At the end of treatment, mice were anesthetized with 87.5 mg/kg 
Ketamine (Henry Schein Inc., Melville, NY) and 12.5 mg/kg Xylazine (Henry 
Schein Inc.) by intraperitoneal injection. One eye of each mouse was then 
injected with microbeads as previously described.65 In brief, mice were stabilized 
on a mounting stage (Stoelting Mouse and Neonatal Rat Adaptor; Stoelting Co., 
Wood Dale, IL) under a zoom-dissecting microscope. A 10μl Hamilton 
microsyringe (Nanofil; World Precision Instruments, Sarasota, FL) was loaded 
with 1μl solution of 20nm microbead tracer (Ex/Em: 505/515, 2%, Invitrogen, 
Carlsbad, CA) diluted 1:50 in Dulbecco's phosphate-buffered saline (v/v), as well 
as 2μl modified Karnovsky’s fixative (2.5% glutaraldehyde and 2% 
paraformaldehyde, pH 7.3) separated by a 0.2μl air bubble. A 35G needle 
(NF35BL- 2; World Precision Instruments) connected to this syringe was then 
inserted into the anterior chamber centrally to optimize uniform distribution. The 
tracer volume was delivered at 4 nL/s by a microprocessor-based microsyringe 
pump controller (Micro4; World Precision Instruments). Artificial tears (Henry 
Schein Inc.) were applied to the cornea of both eyes to prevent dehydration. The 
12 o’clock position of the eye was marked using TMD Tissue Marking Dye 




determine different quadrant. At 30 minutes, half of the original dose of 
anesthesia was administered, in order to maintain the mouse at the appropriate 
level of sedation. After the injection of 1μl of microbeads, 45 minutes were 
allowed for the tracer to migrate through the anterior chamber and strongly 
penetrate the TM and SC. The needle remained in the eye during this period. 1/4 
of the original dose of anesthesia was administered as needed to maintain the 
mouse at the appropriate level of sedation, and 2μl modified Karnovsky’s fixative 
was subsequently injected into the anterior chamber. Modified Karnovsky’s 
fixative was also simultaneously applied to the exterior of the eye multiple times 
using a disposable dropper. After 30 minutes of fixation, the mouse was 
sacrificed, and both eyes were enucleated. The eye injected with microbeads 
was placed in Karnovsky’s fixative while the other eye was placed in 4% 
paraformaldehyde at 4oC overnight. The eyes were then transferred in PBS and 
kept at 4oC for further processing. All following outflow pattern and morphological 
analyses were performed on the eyes after the endpoint of treatment. 
 
Confocal Microscopy 
All microbead-injected eyes were examined using an Olympus MVX10 
(Olympus, Tokyo, Japan) fluorescent stereomicroscope. Eyes without tracer 
present in the TM region were excluded from further processing and analyses. 
Each of the successfully injected eyes (dexamethasone treated group: n=11; 




in Fig. 3-1A. For trabecular outflow imaging, each wedge was immersed in 
mounting media in a glass-bottom dish after the removal of its posterior part and 
imaged in the en face view from the corneal side (yellow surface in Fig. 3-1B) 
with Zeiss LSM 700 (Carl Zeiss, Peabody, MA). The images were taken with a 
10x objective and maximum of pinhole (confocal slice thickness = 143 μm), in 
order to capture the entire fluorescence throughout the thickness of the TM 
tissue. Images were captured and analyzed using the ZEN2010 operating 
software (Carl Zeiss). 
The tissue of all successfully injected eyes from each group was 
subsequently sectioned in both radial (Fig. 3-1C) and frontal (Fig. 3-1D) planes in 
both high tracer and low tracer regions. Two radial and four frontal sections were 
obtained from high tracer and low tracer regions of each eye respectively (four 
radial and eight frontal sections for each eye in total). The obtained radial and 
frontal sections were immersed in Vectashield Antifade mounting medium with 
DAPI (Vector Laboratories, Burlingame, CA) and imaged with Zeiss LSM 700 to 
confirm the presence of high tracer or low tracer. Sections with following 
conditions were excluded from further processing: dilated SC due to the backflow 
of blood into SC, non-exposure of SC in the frontal sections, medium or high 
tracer observed in sections from low tracer region (usually due to the failure of 
precisely dissecting a narrow low tracer region between high tracer regions), or a 










Figure 3-1. Dissection Methods and Imaging Planes.  
A: Pattern of an enucleated eye dissected into eight radial wedges. Trabecular 
meshwork (TM) region and Schlemm’s canal (SC) are demarcated. Analysis of 
one of these eight wedges is illustrated in the following panels. The yellow 
surface represents the side of the tissue seen in the en face view (B), radial 
section (C), and frontal section (D). The frontal section plane is usually bisecting 






tracer penetrating TM (with the majority of tracer adhering to the inner surface of 
the inner most uveal beams).  
 
Analysis of Percentage Effective Filtration Length (PEFL) from confocal images 
In the trabecular outflow images of each radial wedge, ‘‘total length’’ of the 
TM (TL) and ‘‘filtration length’’ of TM containing tracer (FL) were measured using 
ZEN2010. The average percent effective filtration length (TM PEFL= ΣFL/ΣTL x 
100%) in each eye was subsequently calculated as performed in previous 
studies (Fig. 3-2A).58,61 The TM PEFL of each group is the average of all 
successfully injected eyes in the group. 
 
TM Thickness Measurements 
TM thickness was measured from the inner wall (IW) endothelium of SC to 
the innermost uveoscleral beams at the anterior-posterior midline of the TM 
exposed to SC in confocal images of radial sections from both high and low 
tracer regions (Fig. 3-2B). Images that cannot define the edge of TM were 
excluded. At least five different eyes of each group were analyzed. The TM 
thickness of each group is the mean of all analyzed eyes in the group. 
 
Light and Electron Microscopy 
Radial and frontal sections confirmed with high tracer presence or low 
























Figure 3-2. Measurements Methods. 
A: Methods of trabecular meshwork percentage effective filtration length (TM 
PEFL) measurements. The tracer distribution shows as green. The red lines 
represent effective filtration length (FL) labeled with fluorescent tracers, and the 
yellow line represents total length (TL) of the trabecular meshwork (TM). The 
average TM PEFL in each perfused mouse eye was calculated as TM PEFL= 
ΣFL/ΣTL x 100%.  
B: Methods of TM thickness measurements. The yellow double arrow represents 
TM length that is exposed to Schlemm’s canal (SC), and the dotted red line 
represents half of this length. The white double arrow represents the TM 
thickness, the length from the inner wall (IW) endothelium of SC to the innermost 
uveoscleral beams at the anterior-posterior midline of the TM exposed to SC.  
C: Methods of JCT thickness measurements. JCT area (red) and JCT length 
(yellow) were measured in an electron microscopic image, and the average JCT 
thickness (ΣJCT area / ΣJCT length) was then calculated accordingly.  
D: Methods of basement membrane (BM) continuity measurements with confocal 
images. The left panel shows immunohistochemical staining of type IV collagen 
(in green) to label the BM in TM region. The right panel shows the same image 
merged with DAPI staining of nuclei (blue). The yellow double arrows represent 
the full length of the IW of SC, and the red double arrows represent the 





E: Methods of BM continuity measurements with electron microscopic images. 
The yellow double arrows represent full length of the IW of SC, and the red 
double arrows represent the continuous BM length. BM continuity = Σ continuous 






dexamethasone-treated and control eyes respectively were processed for light 
and electron microscopy. Sections were post-fixed with 2% osmium tetroxide and 
1.5% potassium ferrocyanide for 2 hours, en bloc stained with 1.5% uranyl 
acetate for 90 min, dehydrated in an ascending series of ethanol and propylene 
oxide, and embedded in Epon-Araldite. Semithin sections (1 µm) were cut and 
stained with 0.1% Toluidine Blue (Fisher Scientific, Hampton, NH). Light 
microscope images were taken using a 20X objective along the inner wall of SC 
with FSX-100 microscope (Olympus). Sections containing regions of interest 
were then prepared for electron microscopy (at least one radial section from high 
tracer region and one radial section from low tracer region were imaged using 
electron microscopy for each randomly selected eye); ultrathin sections (80 nm) 
were produced, stained with 4% methanol-based uranyl acetate to visualize 
extracellular matrix, and examined using transmission electron microscopes 
(JEOL JEM-1010, Tokyo, Japan). Images were taken along SC at original 
magnifications of 3000X, 5000X, and 10000X. 
 
Measurements of the JCT Thickness  
JCT area was measured in 3000X electron microscopic images of radial 
sections by selecting the area from the basal side of the IW endothelium to the 
empty space adjacent to the outermost corneoscleral beams and measuring the 
cross-section area using ImageJ (NIH). JCT length was also measured in 




a clear outmost beam were used for JCT thickness measurements. At least 
30μm length of JCT was measured for each section. The JCT thickness of each 
group is the mean of the radial sections of 5 eyes. 
 
Immunohistochemistry 
The non-injected eye from each mouse was immersion-fixed immediately 
after enucleation with 4% paraformaldehyde for immunohistochemistry. The eyes 
were then paraffin-embedded, and 5 μm transverse sections were obtained from 
five randomly-selected eyes from each group. Before staining, the paraffin 
sections were deparaffinized in xylene, rehydrated, and washed in PBS. The 
sections were microwaved in 10mM citrate buffer (pH 6.0) for 10 min to retrieve 
antigen, washed in PBS, and then stained for type IV collagen by methods 
adapted from Overby DR et al.137 In brief, sections were incubated for 1hr in 5% 
BLOTTO (Santa Cruz Biotechnology, Dallas, TX) in PBS at room temperature to 
prevent nonspecific binding. Sections were incubated overnight at 4oC with 
primary rabbit polyclonal antibody against type IV collagen (AB756P; 
MilliporeSigma, Burlington, MA) at a dilution of 1:50. Primary antibody was 
diluted in PBS containing 2% bovine serum albumin (BSA; American 
Bioanalytical, Natick, MA) and 0.02% Triton X-100. Sections were then rinsed 
three times with PBS for 10 minutes each and incubated for 2 hours with Alexa 
Fluor ® 488 donkey anti-rabbit secondary antibody (Invitrogen, Carlsbad, CA) at 




Sections were rinsed in PBS and mounted with DAPI Fluoromount-G mounting 
medium (SouthernBiotech, Birmingham, AL). Specimens were examined and 
imaged with Zeiss LSM 700 (Carl Zeiss). Negative controls were treated 
identically, except that the primary antibody was omitted. 
 
Measurement of Basement Membrane Continuity  
Because type IV collagen is a major constituent of basement 
membrane171,172, basement membrane of the IW of SC can be labeled by 
immunohistochemistry staining of type IV collagen. Confocal images taken with a 
40X objective were used to measure the IW length and continuous basement 
membrane (BM) length. At least 100μm of IW length was measured in each 
section. BM continuity was then calculated as Σ continuous BM length / Σ IW 
length x100% (Fig. 3-2D). BM continuity was also measured by using 3000X 
TEM images of radial sections at high tracer and low tracer regions with similar 
methods (Fig. 3-2E). Sections of five randomly selected eyes from each group 
were analyzed. At least 40μm of IW length was analyzed in each section. 
 
Statistical Analysis 
Paired and Non-paired student’s t-test and three-way ANOVA were 
applied for IOP comparison. Mann-Whitney test and Wilcoxon signed rank test 
were applied for hydrodynamic and morphological comparison. Multiple 




applied for correlation analyses. All statistical analyses used GraphPad Prism 7 
(GraphPad Software, San Diego, CA) with a required significance level of p < 
0.05. All data are shown as mean ± SEM. 
 
3-3: Results 
Dexamethasone Treatment Elevates Intraocular Pressure 
Because each eye responds differently to treatment, each eye of a mouse 
can be measured as an independent sample.138 IOP of both dexamethasone-
treated and control groups (N=28 each) was measured at baseline and weekly 
for five weeks following dexamethasone or saline application (Fig. 3-3). IOP 
increased within a week and remained elevated for the following four weeks in 
the dexamethasone-treated group, while remaining unchanged in the control 
group. IOP of the dexamethasone group versus the saline group was 13.9±0.4 
vs. 13.9±0.4 mm Hg (p=1, two-tailed, non-paired t-test) at baseline, 16.4±0.7 vs. 
14.0±0.4 (p=0.003) at week1 after treatment, 16.9±0.4 vs. 13.5±0.4 (p<0.0001) at 
week2 after treatment, 17.7±0.6 vs. 13.5±0.3 (p<0.0001) at week3 after 
treatment, 17.8±0.4 vs. 13.5±0.3 (p<0.0001) at week4 after treatment, and 
17.7±0.4 vs. 13.7±0.3 (p<0.0001) at week5 after treatment. When compared to 
its own baseline, the dexamethasone group showed a significant increase after 
one week treatment (p= 0.006 at week1, <0.0001 at week2, <0.0001 at week3, 
<0.0001 at week4, and <0.0001 at week5, two-tailed, paired t-test). In contrast, 




when compared to its own baseline (p= 0.79 at week1, 0.54 at week2, 0.40 at 
week3, 0.51 at week 4, and 0.66 at week5). 
IOP change during five weeks’ treatment was further analyzed by using 
three-way ANOVA with three factors namely, treatment (dexamethasone vs. 
saline), time, and gender. The results showed that there was a significant main 
effect of the type of treatment, F (1, 312) = 149.9, p < 0.0001. There was also a 
significant main effect of time, F (5, 312) = 5.036, p = 0.0002, while no significant 
main effect of gender, F (1, 312) = 1.349, p = 0.2463. Therefore, eyes from both 
genders were combined for other analyses. And there was a significant 
interaction between the type of treatment and time, F (5, 312) = 7.37, p < 0.0001. 
No significant interaction was found between time and gender [F (5, 312) = 
1.331, p = 0.2508] or between the type of treatment and gender [F (1, 312) = 
2.551, p = 0.1113]. There was no significant interaction between the type of 
treatment, time, and gender, F (5, 312) = 0.6071, p = 0.6946. These data 
suggested that dexamethasone increased IOP significantly over time, while 
different gender did not affect the IOP change.  
 
Dexamethasone Treatment Reduces Outflow Pattern and Percent Effective 
Filtration Length (PEFL) 
 The en face images of the anterior segment showed the outflow pattern in 




control eyes, but the flow pattern was more continuous in the control eyes when 
compared to dexamethasone-treated eyes (Fig. 3-4A).  
 When calculated by using en face confocal images, TM PEFL was 
49.89±4.59% in the dexamethasone group (n=11), which was significantly less 
when compared to the control group TM PEFL of 77.74±2.73% (n=9; p = 0.0005, 
Mann-Whitney test) (Fig. 3-4B). 
Because aqueous outflow in human eyes often times prefers the nasal or 
inferior quadrant, TM PEFL was further analyzed according to different quadrants 
to investigate whether there is a consistent pattern of the aqueous outflow in 
mouse eyes. However, no quadrant preference was found in dexamethasone 
group (superior vs. inferior, p = 0.21; superior vs. nasal, p = 0.24; superior vs. 
temporal, p = 0.06; inferior vs. nasal, p = 0.62; inferior vs. temporal, p = 0.84; 
nasal vs. temporal, p = 0.89; Wilcoxon signed rank test) or saline group (superior 
vs. inferior, p = 0.36; superior vs. nasal, p = 0.20; superior vs. temporal, p = 0.43; 
inferior vs. nasal, p = 0.73; inferior vs. temporal, p = 0.20; nasal vs. temporal, p = 
0.16). By multiple comparison analysis, there was a significant reduction in TM 
PEFL at the superior quadrant after dexamethasone treatment (p = 0.0003), but 
not in TM PEFL at the inferior (p = 0.22), nasal (p = 0.69), or temporal (p = 0.07) 
quadrant (Fig. 3-4C). These results suggest that superior quadrant was affected 
the most by topical dexamethasone, while nasal quadrant was affected the least. 
Guided by the outflow pattern, radial and frontal sections were obtained 










Figure 3-3. IOP Change.  
Dexamethasone treatment increased IOP over time. Dexamethasone-treated 
eyes showed significantly increased IOP at all time points after treatment 
compared to the controls (##: p<0.01; ###: p<0.001). There was also a 



















Figure 3-4. Trabecular Meshwork Percentage Effective Filtration Length (TM 
PEFL).  
A: Representative en face images of saline- and dexamethasone-treated eyes 
(N: nasal; T: temporal; S: superior; I: inferior). B: Dexamethasone treatment 
induced a significant reduction in TM PEFL when compared to controls (***: 
p<0.001). C: When analyzed by quadrant, dexamethasone treatment decreased 






tracer regions in both radial and frontal sections was reduced in the 
dexamethasone-treated eyes when compared to those in the control eyes (Fig. 
3-5). 
 
Effects of Dexamethasone on the Thickness of the Trabecular Meshwork and 
Juxtacanalicular Connective Tissue (JCT) 
TM thickness was measured in high tracer and low tracer regions (Fig. 3-
6A). In high tracer regions, TM thickness was found significantly greater when 
compared to that in low tracer regions, in both dexamethasone group 
(14.33±1.38 vs. 10.01±0.89 µm, p=0.0173, Mann-Whitney test) and control group 
(14.42±0.76 vs. 9.42±0.87 µm, p=0.0027) (Fig. 3-6B). No significant difference 
was found between dexamethasone group and controls, in either high tracer (p = 
0.83) or low tracer regions (p = 0.94). However, since the high tracer regions 
were significantly decreased in dexamethasone group, the estimated overall TM 
thickness would be reduced in dexamethasone group when compared to control 
group. ②
JCT thickness was calculated in high tracer and low tracer regions (Fig 3-
7A). Average JCT thickness in high tracer regions of control eyes (3.05±0.54 µm) 
was greater when compared to that in low tracer regions (1.92±0.17 µm). This 
difference in JCT thickness approached but did not reach statistical significance  
                                                        
② Overall TM thickness was estimated, rather than calculated as TM thickness overall = TM thickness high tracer region X 
IW PEFL + TM thickness low tracer region X (1-IW PEFL). Because only sections with clear edges of TM were used for 
TM thickness measurements, TM thickness high tracer region and TM thickness low tracer region may not be both obtained 















Figure 3-5. Tracer Amount in Trabecular Meshwork.  
Representative confocal images from radial (A) and frontal (B) plane view reveal 
reduced amount of microbeads tracer in the TM region after dexamethasone 
treatment. The green represents the tracer distribution. The blue represents 














Figure 3-6. Trabecular Meshwork Thickness.  
A: Representative confocal images from radial section show the TM thickness 
measurements in high tracer vs. low tracer regions of control and treated eyes.  
B: In both treated and control eyes, TM thickness in high tracer regions was 
significantly higher when compared to low tracer regions (*: p < 0.05; **: p < 



















Figure 3-7. Juxtacanalicular Connective Tissue (JCT) Thickness.  
A: Representative electron microscope images of JCT from low tracer and high 
tracer regions of saline control (left column) and dexamethasone treated (right 
column) eyes. Bottom row presents a larger view of the squared region in middle 
row. The presence of tracers is indicated with black arrows. B: A more expanded 
JCT was found in the high tracer regions than low tracer regions in control eyes. 
Dexamethasone treatment induced a significant reduction in the JCT thickness in 
high tracer regions compared to high tracer regions in control eyes (*: p<0.05) 
(n=5). C: The average overall JCT thickness was decreased in dexamethasone 






(p=0.0625, Wilcoxon signed rank test) (Fig. 3-7B). No significant difference in 
JCT thickness was found between high and low tracer regions in 
dexamethasone-treated eyes (p=0.44). In dexamethasone-treated eyes, mean 
JCT thickness in low tracer regions was similar to control eyes (1.67±0.33 µm, 
p=0.15, Mann-Whitney test), while mean JCT thickness in high tracer regions of 
dexamethasone-treated eyes was significantly decreased when compared to the 
high tracer regions of controls (1.82±0.28 vs. 3.05±0.54 µm, p=0.0317) (Fig. 3-
7B). The mean overall JCT thickness [JCT thickness overall = JCT thickness high 
tracer region x PEFL + JCT thickness low tracer region x (1-PEFL)] was decreased after 
dexamethasone treatment when compared to controls (1.77±0.20 µm vs. 
2.85±0.46 µm), but this decrease did not reach statistical significance (p = 0.095) 
(Fig. 3-7C). 
 
Dexamethasone Treatment Alters Extracellular Matrix Structure in Trabecular 
Meshwork 
Several morphological changes were discovered in the ECM of TM region 
after dexamethasone treatment, including the increase of deposition of curly 
collagen and/or fibrillary structure, and increased basement membrane 
continuity. 
Curly collagen, or long-spacing collagen, is found mostly in pathological 
conditions, such as in the trabecular meshwork of glaucomatous eyes, although 




the formation of curly collagen in the JCT region in two out of five 
dexamethasone-treated eyes, but in none of five control eyes (Fig. 3-8A). 
Although curly collagen was observed in both high tracer and low tracer region of 
dexamethasone-treated eyes, it was more abundant in low tracer regions. The 
increased deposition of fibrillary structures in the low tracer regions was also 
observed in three out of five dexamethasone-treated eyes (Fig 3-8B). 
The basement membrane (BM) of the inner wall endothelium of SC has a 
potential to generate resistance to the aqueous outflow. Although the BM of the 
inner wall is patchy and discontinuous,33,176,177 increased BM continuity has been 
previously reported in a systemically-induced steroid ocular hypertensive mouse 
model.137 BM continuity was first calculated in the eyes without tracer injection by 
using immunohistochemistry staining of type IV collagen, a major component of 
BM. However, there was a large variance in BM continuity of both saline and 
dexamethasone groups (Fig. 3-9A). However, there was a trend for a greater 
mean BM continuity in dexamethasone-treated eyes (49.19±5.54%, range 36.73-
65.16%) compared to controls (25.69±7.37%, range 7.04-49.72%). This 
difference in BM continuity approached but did not reach statistical significance 
(p=0.0556, Mann-Whitney test) (Fig. 3-9B). Since the eyes used for Type IV 
collagen staining were not labeled with tracer, the BM continuity was further 
investigated in EM images in high and low tracer regions. In saline-treated eyes, 
while BM often times was discontinuous in high tracer regions, more continuous 












Figure 3-8. Extracellular Matrix Morphology in both Dexamethasone-
Treated and Control Eyes.  
A: Representative electronic microscope images show the formation of curly 
collagen (white asterisks) in JCT region of dexamethasone-treated eyes, while 
the normal type I collagen bundles (white arrows) present in JCT region of 
control eyes. B: Representative EM images show the increased deposition of 
fibrillary structures (black arrows) in the low tracer region of dexamethasone-












Figure 3-9. Basement Membrane Continuity by Immunohistochemistry. 
A: Representative confocal images show that BM continuity varies in both 
dexamethasone-treated and untreated eyes. The green represents positive 
staining of type IV collagen, a major component of BM. The blue represents 
nuclei. The white arrows indicate the continuous BM. (SC: Schlemm’s canal) B: 
Mean BM continuity was higher in dexamethasone-treated eyes when compared 





















Figure 3-10. Basement Membrane Continuity by Using Electron 
Microscopy.  
A: Representative electron microscope images around inner wall of Schlemm’s 
canal (SC) from high tracer and low tracer regions of saline- and 
dexamethasone-treated eyes. Black arrows indicate the continuous BM. White 
arrows indicate fibrillary BM-like structure formed after dexamethasone 
treatment. B: Dexamethasone treatment induced a significant increase in BM 
continuity in high tracer regions compared to that in high tracer regions in control 
eyes (**: p<0.01, n=5). C: The overall BM continuity was significantly increased 
in dexamethasone-treated eyes when compared to the controls (**: p<0.01, n=5). 
D: There was a significant negative correlation between TM PEFL and overall 






eyes, besides the increased continuity of regular BM, there was formation of 
continuous fibrillary BM-like structure observed in both high tracer and low tracer 
regions. Because this fibrillary BM-like structure was difficult to distinguish from 
the regular BM sometimes, it was also included as continuous BM when we 
calculated the BM continuity by using TEM images. In the saline-treated eyes, 
there was trend for the mean BM continuity to be greater in low tracer regions 
when compared to high tracer regions (62.26±6.40% vs. 26.88±1.96%). 
However, this difference in BM continuity approached but did not reach statistical 
significance (p=0.0625, Wilcoxon signed rank test) (Fig. 3-10B). The difference in 
BM continuity between low tracer and high tracer regions in dexamethasone-
treated eyes also approached but did not reach statistical significance 
(77.14±4.66% vs. 49.45±2.30%, p=0.0625). In dexamethasone-treated eyes, 
mean BM continuity in low tracer regions was similar to control eyes 
(77.14±4.66% vs. 62.26±6.40%, p=0.15, Mann-Whitney test), while mean BM 
continuity in high tracer regions of dexamethasone-treated eyes was significantly 
greater when compared to the high tracer regions of controls (49.45±2.30% vs. 
26.88±1.96%, p=0.0079) (Fig. 3-10B). The overall BM continuity was calculated 
as BM continuity overall = BM continuity high tracer region x PEFL + BM continuity low 
tracer region x (1-PEFL)].  Overall BM continuity was significantly increased after 
dexamethasone treatment when compared to controls (64.13±3.68% vs. 








In this study, we investigated the chronic effects of topical steroid, 
dexamethasone, on IOP, outflow pattern, and trabecular meshwork morphology 
in vivo in mouse eyes. Dexamethasone treatment induced ~4 mm Hg increase in 
IOP. As we hypothesized, this steroid-induced IOP elevation was associated with 
reduced active filtration areas in trabecular meshwork. Steroid application 
induced ~1/3 reduction in TM PEFL. While no quadrant preference was found in 
the outflow pattern, this reduction in active filtration areas induced by steroid was 
most significant in the superior quadrant. With further investigation of 
ultrastructure changes in the trabecular meshwork, we found that steroid 
treatment caused a decrease in the JCT thickness in high tracer regions. 
Additionally, we found abnormal accumulation of ECM in trabecular meshwork of 
steroid-treated eyes, including curly collagen, fibrillary structures, and IW 
basement membrane. There was a significant negative correlation between TM 
PEFL and BM continuity. These data support our hypothesis that elevated IOP 
induced by steroid treatment is associated with morphological changes in the 
trabecular outflow pathway that cause a reduction in active filtration areas in the 




 Similar to our previous study on ocular hypotensive SPARC-null mice, we 
found an inverse relationship between IOP and TM PEFL. However, although 
this relationship was statistically significant (p = 0.0025, linear regression), the 
correlation between IOP and TM PEFL (R2 = 0.41, Fig. 3-11A) was much weaker 
when compared the correlation between IOP and TM PEFL reported in the 
previous study (R2 = 0.72). Meanwhile, although we found a strong correlation 
between TM PEFL and overall BM continuity (R2 = 0.83, Fig. 3-10D), the 
correlation between IOP and overall BM continuity was also relatively weak (R2 = 
0.48, p = 0.03, Fig. 3-11 B). There are two possible causes for these weak 
correlations between IOP and either TM PEFL or BM continuity in the current 
study. First, the microbeads tracer was injected into mouse eyes when the mice 
were anesthetized by ketamine + xylazine. General anesthetics are known to 
reduce IOP. IOP falls further as deeper levels of anesthesia are attained. The 
decrease in IOP is attributed to an increase in outflow facility,178 relaxation of the 
extraocular muscles,178 and a decrease in the rate of aqueous humor 
formation.179,180 However, this IOP reduction induced by general anesthetics 
seems more significant on rodents with elevated IOP when compared to normal 
IOP controls 138,170,181. Therefore, the actual IOP of steroid-treated eyes during 
microbeads injection may decrease more when compared to the control eyes, 
causing a weaker correlation between the IOP measured before anesthesia and 
TM PEFL/BM continuity. Secondly, this current study focused on the effects of 












Figure 3-11. Correlation between Intraocular Pressure and TM PEFL.  
A: TM PEFL was found to have a significant but weak negative correlation with 
IOP (R2 = 0.41, p = 0.0025).  B: Overall BM continuity was positively correlated 






unneglectable. The TM PEFL and BM continuity are supposed to correlate with 
trabecular outflow facility (C trabecular). The assumption of linear correlation 
between IOP and trabecular outflow facility was based on the modified 
Goldmann equation [Flowrate total = (IOP-P ESV) C trabecular + Flowrate uveoscleral]. 
This equation has an assumption that uveoscleral flowrate is independent from 
IOP. However, direct tracer-based measurements indicate that uveoscleral 
outflow is not entirely pressure-independent, although it is relatively pressure-
insensitive.182–185 Also, the uveoscleral outflow accounts for a much greater 
portion of the total aqueous outflow in mouse eyes (~66%).165,186 Therefore, it is 
possible that the relationship between IOP and TM PEFL/BM continuity is non-
linear due to the IOP-dependent influence of uveoscleral outflow, resulting in a 
weaker linear correlation, especially when eyes with elevated IOP were involved. 
 Also consistent with the results in SPARC-null mice study, we did not find 
any quadrant preference in TM PEFL in control eyes. Although we found that 
steroid treatment reduced TM PEFL most significantly in the superior quadrant, 
this current study was designed to conduct morphological comparison between 
high tracer and low tracer regions rather than between different quadrants. 
Further studies need to be conducted to investigate the possible functional and 
morphological differences between the superior quadrant and other quadrants. 
 The average TM PEFL in control eyes calculated in this current study was 
greater than that calculated in SPARC-null mice study (77.74±2.73% vs 




in the methods of SPARC-null mice study: “Tracer-containing TM was included in 
the measurement only if the fluorescence created a clear banded pattern and if 
confocal microscopy confirmed microbead deposition along the JCT and inner 
wall of SC; irregular, hazy points of fluorescence were not included.” All tracer-
containing TM length was measured as filtration length in this current study. 
 Although this current study aimed to investigate the effects of topical 
steroid on mouse eyes, we would expect that some systemic effects of steroids 
were also involved due to the self-grooming behavior of rodents and possible 
diffusion of steroid into the circulatory system. Systemic administration of steroid 
was shown to decrease the body weight in mice.136,137 About 40% of the 
dexamethasone-treated mice were eliminated from one of the previous systemic 
steroid studies, because more than 20% body weight loss was found in these 
mice by 3-4 weeks.137 In this current study, the body weight of the steroid-treated 
group exhibited ~10% body weight loss when compared to controls, indicating 
the presence of systemic effects of steroid. However, none of these animals in 
the current study were found in critical health condition due to body weight loss, 
which was much less than that in systemic delivery of steroid model used in 
previous studies136,137. Furthermore, systemic therapy of steroids is the least 
likely route to cause IOP elevation in clinic.118 Therefore, topical steroid model 
can be a more valuable model for mechanism and therapy study on steroid-
induced ocular hypertension. Recently, Patel GC et al. reported a novel method 




injections, which may cause the elevation of IOP without decreasing body 
weight.187  
 The major ultrastructural changes in the TM associated with steroid 
treatment were found to be a more compacted JCT in high tracer regions and 
increased deposition of ECM. The latter is consistent with previous findings on 
steroids’ effects on ECM in TM cell culture.117,188,189 These morphological 
correlations are very likely to contribute to the increase in resistance to outflow 
and result in a reduced EFA. Curly collagen was previously found to contain type 
VI collagen173 and similar components of the plaque material underneath the 
inner wall of SC, which were shown to be significantly more abundant in 
glaucomatous eyes. 190 Type VI collagen has a tendency to form aggregates by 
forming extensive intramolecular disulfide bonds and has a high resistance to 
proteolytic enzymes 173. Although the composition of the fibrillary structures that 
we observed to be increased in the low tracer region of dexamethasone-treated 
eyes is unclear, the structures appeared to be similar to the basement 
membrane. Therefore, we will hypothesize that they may contain similar 
components to basement membrane, such as type IV collagen, perlecan, 
laminin, integrins etc. However, further immuno-labeling studies will be needed to 
confirm this hypothesis. Both the observation of formation of curly collagen and 
increased BM continuity were consistent with the previous findings from a study 
on systemic dexamethasone-induced ultrastructural changes in mouse eyes.137 




eyes and 75.7±8.3% in systemic dexamethasone treatment. The BM continuity in 
controls was similar to the overall BM continuity we calculated (33.96±2.27%), 
while the BM continuity in systemic dexamethasone-treated eyes was slightly 
greater than the overall BM continuity that we calculated in topical 
dexamethasone-treated eyes (64.13±3.68%). The difference in BM continuity 
measured with EM microscopy between this study and previous systemic steroid 
study is likely due to the difference in sampling methods. The increase in BM 
continuity may imply the increase of cell-matrix connections between inner wall of 
SC to the ECM in JCT, which may elevate the outflow resistance. This is 
consistent with the previous report showing that dexamethasone induces focal 
adhesions in cell culture, via which cells connect to the matrix.191 By labeling the 
outflow pattern in this current study, we further found that this increase in BM 
continuity mostly occurred in the high tracer regions after dexamethasone 
treatment, which was consistent with our observations of less tracer present in 
the TM region, even in the high tracer regions of dexamethasone-treated eyes 
when compared to those of controls (Fig. 3-5). Previous study also provided 
evidence of the increased BM continuity in human steroid-induced glaucomatous 
eyes.137 Previous systemic dexamethasone treatment study reported a significant 
negative correlation between the outflow facility of ex vivo perfused mouse eyes 
and BM continuity, which is similar to the negative correlation between TM PEFL 
and overall BM continuity found in this study. Previous systemic dexamethasone 




dexamethasone-treated eyes.137 In our current study, with the association of 
more compacted JCT thickness in high tracer region and the increase of 
deposition of ECM, we would also expect the empty space in dexamethasone-
treated eyes to be reduced, especially in high tracer regions. This can also cause 
an increase in outflow resistance in JCT. 
However, while the previous systemic dexamethasone treatment study 
indicated that the immunohistochemistry staining of type IV collagen was more 
continuous along the inner wall of SC when compared to the controls, we found a 
relatively large variance in BM continuity in both dexamethasone-treated and 
control eyes by type IV collagen immunohistochemistry staining (Fig. 3-9). 
According to the BM continuity measured with EM images, the more 
discontinuous type IV collagen staining along the inner wall should be associated 
with high tracer regions, while the more continuous staining should be associated 
with low tracer regions. However, because the immunohistochemistry analysis in 
our current study was performed on the eyes without microbeads injection, we 
could not directly correlate the type IV collagen staining with outflow dynamics. 
Further study with immunostaining of the tracer-injected eyes is required to 
investigate whether the more continuous type IV collagen staining can be 
correlated with low tracer regions.  
Unlike the previous experiments employing ex vivo perfusion on systemic 
dexamethasone-treated mouse eyes,137 our anterior chamber injection was 




was present and the ESV pressure was not zero. However, the limitation is that 
the exact effects of steroid treatment and elevated IOP on the aqueous humor 
production rate and ESV pressure were not clear. According to previous studies, 
no significant differences in aqueous humor production was found between 
glaucomatous human eyes and age-matched healthy controls,192,193 while 
increased aqueous humor production rate was found in the glaucomatous eyes 
at night when compared to the controls.192 Meanwhile, there was a nonsignificant 
increase in ESV pressure was found in glaucomatous patients when compared to 
age-matched controls.193 Therefore, we may assume that the effects of 
dexamethasone treatment and induced IOP elevation on aqueous humor 
production rate and ESV pressure to be negligible, although direct evidence to 
confirm this assumption may be needed in the mouse eyes. As we discussed 
previously, the effects of anesthesia during anterior chamber injection on the 
mouse eyes with elevated IOP may be greater than on the control eyes.138,170 
Although the injected solution containing microbeads tracers may increase actual 
IOP in the mouse eyes, which equals to an increase of 4nl/sec in the aqueous 
outflow production rate, this increase in IOP in dexamethasone-treated eyes is 
supposed to be the same as that in control eyes. In terms of the uveoscleral 
outflow, as we previously discussed, it accounts for a greater proportion in 
mouse eyes when compared to human eyes.165,186 Uveoscleral outflow rate was 
shown to be greater at lower IOP in mouse eyes.165 Consistently, reduced 




A notable limitation of this study is that for ultrastructure analysis, the two 
radial sections (one from high tracer region, the other from low tracer region) only 
count a small fraction of the total TM. And the sample size (n=5) is relatively 
small as well. 
 In summary, we found that the topical dexamethasone treatment 
increases IOP chronically in mouse eyes by reducing the area of active filtration 
in the trabecular outflow pathway. Morphological correlations with this reduction 
include compacting the JCT in high tracer regions and increasing deposition of 
ECM in the TM. A significant decrease in PEFL was found in the superior 
quadrant of the eye, suggesting morphological correlations that distinguish the 
superior quadrant from other quadrants, which needs to be confirmed with further 
study. Similar ultrastructural changes were found in topical dexamethasone-
treated mouse eyes when compared to both systemic dexamethasone-treated 
mouse eyes and human eyes with steroid-induced glaucoma. Our data 
demonstrate that dexamethasone may increase outflow resistance in JCT/TM via 
both increasing cell-matrix connections between inner wall cells and JCT ECM 
and decreasing empty space in JCT by increasing ECM deposition and 
compacting JCT. More importantly, our data suggest that steroid treatment 
affects morphology more significantly in high tracer regions and these 
morphological changes did result in a reduction of EFA. Results of this study 




outflow regulation in mouse eyes and directions to further mechanisms and/or 





CHAPTER FOUR: Additional Studies and Future Researches 
4-1: Sphingosine-1-phosphate (S1P) reduces outflow facility Introduction. 
Introduction 
In order to investigate whether PEFL and morphological changes are 
correlated to outflow facility reduction induced by the elevation of outflow 
resistance, we propose to investigate the effects of Sphingosine-1-phosphate 
(S1P) on the hydrodynamics and trabecular outflow pathway morphologies in 
bovine and human eyes. S1P is a lysophospholipid that has been detected in the 
aqueous humor of normal eyes195,196 and was previously reported to decrease 
outflow facility in perfused porcine,197 mouse,198 and human199 eyes. A recent 
study showed that elevated level of S1P was found in the aqueous humor of 
ocular hypertensive mouse eyes.196 An antagonist that specifically binds the 
S1P2 subtype receptor was found to block the S1P-induced decrease of outflow 
facility in porcine, mouse, and human whole-eye perfusions.198,200 These data 
suggest that the conventional outflow pathway has the potential to utilize S1P as 
a signaling molecule to modulate outflow resistance via S1P2 receptor activation. 
In cultured human TM cells, S1P induces Rho activation, thus promoting myosin 
light chain (MLC) phosphorylation and increased stress fiber formation.197 In 
cultured SC cells, S1P increases MLC phosphorylation, while also promoting a 
cortical rearrangement of the actomyosin system.48 Both MLC phosphorylation 
and the actomyosin rearrangement affect cytoskeleton dynamics and intercellular 




resistance. S1P can also regulate endothelial barrier via Cdc42/Rac signaling 
pathway.201,202 Although no consistent difference was found in abundance and 
location of cytoskeleton or junctional proteins, such as F-actin, β-catenin, and 
VE-cadherin between S1P perfused human eyes and controls in a previous 
study,199 the authors stated that it might due to the fact that they were not able to 
mark the outflow pathway with tracer, which may cause the morphological 
differences to be overlooked through random or quadratic sampling strategies. 
Our fluorophore-guided imaging technique has obvious advantages when solving 
such problems. In addition, MLC phosphorylation has not been studied in S1P 
perfused human eyes yet. Furthermore, S1P can induce constriction of blood 
vessels203 and lymphatic vessels204 via S1P2 receptor activation. Therefore, S1P 
has the potential to increase outflow resistance distal to SC by constricting ESVs. 
We propose to study the hydrodynamics and associated morphological changes 
at multiple locations along the trabecular outflow pathway when reducing outflow 
facility by S1P perfusion in bovine and human eyes. Due to its Rho and Rac 
activator function, we hypothesize that S1P will induce structural changes in 
perfused bovine and human eyes, resulting in a decrease in the effective filtration 
area in the trabecular outflow pathway and thereby, a decrease in outflow facility. 
 
Preliminary Studies 




Six pairs of freshly enucleated bovine eyes were initially perfused with GPBS 
for 30 minutes at 15 mm Hg to establish a stable baseline facility. Anterior 
chamber fluid of one eye of each pair was exchanged with 7ml of 5µM S1P 
(Sigma-Aldrich, St. Louis, MO) and followed by perfusion of the same solution for 
2 hours at constant pressure (15 mm Hg). The contralateral eye of each pair was 
exchanged and perfused with GPBS as control. To label the hydrodynamic 
outflow, anterior chamber fluid from all eyes was then exchanged for 7ml of 
FluoSpheres® Carboxylate-Modified Microspheres (Ex/Em: 505/515, 200 nm in 
size, Molecular Probes, Eugene, OR) at 0.002% vol/vol concentration followed by 
perfusion of 500µl of the same solution. All eyes were then perfusion-fixed with 
4% paraformaldehyde for 30min. After perfusion was completed, a small cut was 
made along the equator, and each eye was immersed in the same fixative 
overnight. All eyes were then stored in PBS at 4oC until further processing. 
Anterior segment from each eye were further dissected into 16 radial wedges, 
four from each quadrant. All radial wedges were cut for frontal sections to bisect 
SC and TM.58,149 Each frontal section was then counterstained with DAPI and 
examined by confocal microscopy (LSM700, Carl Zeiss) to measure IW 
PEFL.58,61 During baseline setup and perfusion, outflow of both S1P-treated and 
control groups was continually measured, and outflow facility was calculated at 
baseline, upon S1P or GPBS application, and once every 10min afterwards (Fig. 
4-1A). Our preliminary data showed that while outflow facility increased over time 




outflow facility increases with the volume of perfusate flowing through the outflow 
pathways in experimentally perfused non-human eyes,13,14,15 outflow facility in 
the S1P-treated group only slightly increased after 90min of perfusion. Outflow 
facility of the S1P group versus the GPBS group was 1.27±0.13 vs. 1.56±0.15 
µl/min/mm Hg (p=0.31, Wilcoxon Signed Rank test) at baseline, 1.49±0.14 vs. 
2.32±0.39 (p=0.03125) at 0min after perfusion, 1.54±0.20 vs. 2.45±0.40 
(p=0.0625) at 10min after perfusion, 1.56±0.19 vs. 2.48±0.31 (p=0.03125) at 
20min after perfusion, 1.52±0.18 vs. 2.62±0.33 (p=0.03125) at 30min after 
perfusion, 1.54±0.20 vs. 2.78±0.34 (p=0.03125) at 40min after perfusion, 
1.58±0.20 vs. 2.97±0.35 (p=0.03125) at 50min after perfusion, 1.60±0.23 vs. 
3.10±0.34 (p=0.03125) at 60min after perfusion, 1.61±0.23 vs. 3.27±0.35 
(p=0.03125) at 70min after perfusion, 1.63±0.37 vs. 3.44±0.37 (p=0.03125) at 
80min after perfusion, 1.71±0.24 vs. 3.58±0.36 (p=0.03125) at 90min after 
perfusion, 1.81±0.24 vs. 3.73±0.39 (p=0.03125) at 100min after perfusion, 
1.89±0.25 vs. 3.96±0.40 (p=0.03125) at 110min after perfusion, and 1.93±0.27 
vs. 4.19±0.43 (p=0.03125) at 120min after perfusion. Outflow facility increased 
169% from its baseline after 2 hours of perfusion in control eyes, while increased 
only 52% in S1P-perfused eyes (Fig. 4-1B). There was a 10min interval between 
the real start point of perfusion after exchange and 0min after perfusion time 
point, because the system needs to auto-adjust to 15 mm Hg constant pressure. 
Among these six pairs of bovine eyes, two pairs were perfused by a previous 




calculated by the previous student showed a decrease in S1P treated eyes when 
compared to the control (27.67% and 15.81% vs. 48.23% and 51.90%).208  
2. Effect of S1P on outflow facility and EFA in human eye: 
One pair of enucleated human eyes from an anonymous donor was 
obtained from the National Disease Research Interchange (Philadelphia, PA). 
The donor was a female Caucasian, 71-year old, with no known history of ocular 
disease or surgery. The postmortem time to the beginning of perfusion was 30 
hours. Both eyes were initially perfused with GPBS for 30 minutes at 15 mm Hg 
to establish a stable baseline facility. Anterior chamber fluid of one eye was 
exchanged with 5ml of 5µM S1P and followed by perfusion of the same solution 
for 3 hours at constant pressure (15 mm Hg). The contralateral eye was 
exchanged and perfused with GPBS as a control. To label the hydrodynamic 
outflow, anterior chamber fluid from both eyes was then exchanged for 5ml of 
FluoSpheres® Microspheres at 0.002% vol/vol concentration followed by 
perfusing 150µl of the same solution. Both eyes were then perfusion-fixed with 
4% paraformaldehyde for 30min. During baseline setup and perfusion, outflow of 
both S1P-treated and control eyes was continually measured and outflow facility 
was calculated at baseline, upon S1P or GPBS application, and once every 
10min afterwards (Fig. 4-2A, Table 4-1). After perfusion was completed, a small 
cut was made along the equator, and each eye was immersed in the same 










Figure 4-1. S1P induced outflow facility change in bovine eyes.  
A: Outflow facility in control eyes increased over time. S1P-treated eyes showed 
significantly decreased outflow facility almost at all time-points compared to the 
controls (*: p<0.05). B: The outflow facility was significantly lower in S1P-treated 







processing. Eyes were first dissected along the equator into anterior and 
posterior segments. Anterior segments were further processed by removing the 
iris, ciliary body, cornea (with a 10 mm trephine), vitreous, and excess 
conjunctiva. To visualize active outflow areas, the remaining anterior segments 
were then imaged globally with blue LED epi-illumination on both their scleral 
(anterior view) and TM (posterior view) surfaces with a fixed exposure time of 5 
seconds (Fig. 4-2B) using a 300mm lens on a 4000MP VersaDock imaging 
system. Our preliminary data showed that 3hrs of perfusion, outflow facility in the 
control eye was 0.147 µl/min/mm Hg, which showed a 35.5% reduction from its 
own baseline facility (0.228 µl/min/mm Hg), while outflow facility in the S1P-
treated eye was 0.094 µl/min/mm Hg, a 65.0% reduction from its own baseline 
facility (0.268 µl/min/mm Hg) (Table 4-1, Fig. 4-2A). Reduced active outflow area 
was also observed on the anterior view global image of the S1P-treated eye 
when compared to the control (Fig. 4-2B).  
 
Summary & Discussion 
The preliminary data of this study suggest that S1P induces a reduction in 
outflow facility in both bovine and human eyes as we hypothesized. Correlated 
with this reduction in outflow facility, the active outflow area at the inner wall of 
SC and at ESV may be also reduced. However, for the bovine eyes, further 
hydrodynamic and morphological analyses will need to be completed to 




Table 4-1. Outflow facility change over time in human eyes. (unit: µl/min/mm Hg) 
Time (min) after perfusion GPBS S1P 
Baseline 0.228 0.268 
0 0.207 0.218 
10 0.203 0.189 
20 0.186 0.195 
30 0.179 0.178 
40 0.171 0.208 
50 0.163 0.173 
60 0.130 0.142 
70 0.142 0.096 
80 0.145 0.100 
90 0.138 0.098 
100 0.140 0.102 
110 0.141 0.106 
120 0.138 0.107 
130 0.132 0.094 
140 0.138 0.090 
150 0.140 0.090 
160 0.143 0.088 
170 0.139 0.088 















Figure 4-2. S1P induced outflow facility and outflow pattern change in 
human eyes.  
A: Outflow facility in control eye increased over time. S1P-treated eye showed 
decreased outflow facility almost at all time-points compared to the controls. B: 
Global images of anterior segments of perfused human eyes showing the outflow 
tracer patterns in the posterior [trabecular meshwork (TM)] and anterior 
[episcleral vein (ESV)] views. Reduced effective filtration area was observed on 
the anterior view global image of the S1P-treated eye when compared to the 






EFA along the trabecular outflow pathway. These analyses include IW PEFL 
measurements, TM thickness measurements at high tracer and low tracer 
regions, frozen sectioning and immunostaining for phosphorylated MLC, β-
catenin, VE-cadeherin and F-actin at high tracer and low tracer regions, 
morphological comparison at high tracer and low tracer regions with light and 
electron microscopy. For the human eyes, more donor human eyes will be 
needed for further analyses. Similar subsequent hydrodynamic and 
morphological analyses as for bovine eyes will be needed to investigate the S1P-
induced changes in EFA and the correlated morphological changes in the 
trabecular meshwork of human eyes. In addition, global images and ESV sizes 
will be obtained to investigate the effects of S1P on the distal outflow and 
correlated morphological changes in ESV. The results of this study may reveal 
the S1P-induced morphological changes responsible for the outflow facility 
reduction, provide insights into the mechanisms of trabecular outflow regulation, 
and possibly provide either S1P receptor or a downstream signaling pathway as 
a valuable target for reducing the outflow resistance in glaucomatous patients. 
 
4-2: Steroid-induced ocular hypertension can be rescued by either topical 
administration of Rho kinase inhibitor or suspension of steroid treatment. 
Introduction 
 Our previous studies demonstrated that Rho kinase inhibitors can 




topical administration of Rho kinase inhibitor can reduce IOP in the steroid-
induced ocular hypertensive mice, and to further investigate the effects of Rho 
kinase inhibitor on the outflow pattern and morphology of the trabecular outflow 
pathway in eyes with elevated IOP. In order to avoid the effects of netasudil’s 
NET inhibitor function on hydrodynamics, we chose to use AR12286, a Rho 
kinase inhibitor shown to be able to reduce IOP in glaucomatous patients.210,211 
Since suspension of steroid administration can reduce IOP in the majority of 
steroid-induced ocular hypertension patients, we use suspension of steroid 
administration as a control to compare the effect between the suspension of 
dexamethasone treatment and a Rho kinase inhibitor, AR12286 treat on IOP 
reduction in the steroid-induced ocular hypertensive mouse model. 
 
Preliminary Studies 
Forty-four 6-week old C57BL/6 mice were randomly divided into four 
groups: saline-treated control group (n=11), dexamethasone-treated group (n=8), 
dexamethasone-AR12286 group (n=14), and dexamethasone-suspension group 
(n= 11). Each group included both males and females. A small eye drop (∼10 μl) 
of either 0.1% dexamethasone phosphate (Henry Schein Inc.; dexamethasone-
treated, dexamethasone-suspension, and dexamethasone-AR12286 groups) or 
sterile saline (both containing 9.4mg/ml hydroxyethyl cellulose) was topically 
applied to both eyes of each mouse twice per day for 4 weeks. The initial daily 




pm and 4:30 pm. At week 5, the control group was treated with saline four times 
a day, the two additional doses were between 11 am and noon and between 5 
pm and 7 pm, respectively. Dexamethasone-treated group was treated with two 
doses of saline in addition to the two doses of dexamethasone treatment each 
day, while dexamethasone-AR12286 group was treated with two additional 
doses of 0.25% AR12286 (containing 9.4mg/ml hydroxyethyl cellulose). There 
was no additional treatment for dexamethasone-suspension group in week 5. 
After the initial baseline IOP measurement, IOP was measured weekly between 
8 am and 10 am using a rodent rebound tonometer (Icare, Vantaa, Finland). 
Each eye of a mouse was treated as an independent subject for IOP 
measurements (N= 22 for control group, 16 for dexamethasone-treated group, 28 
for dexamethasone-AR12286 group, and 22 for dexamethasone-suspension 
group, respectively). At the endpoint of treatment, one eye of each mouse was 
anterior chamber injected with 1μl of microbeads tracer as previously described. 
However, for the dexamethasone-suspension group, we did not inject tracer until 
their IOPs were returned to the same level as control eyes.  The eye with 
microbeads injected was fixed with modified Karnovsky’s fixative, enucleated, 
and placed in modified Karnovsky’s fixative at 4oC overnight. The other eye was 
enucleated and placed in 4% paraformaldehyde at 4oC overnight. All eyes were 
then kept in PBS at 4oC for further processing.  
Our preliminary data showed that IOP increased within a week and remained 




remaining unchanged in the control group (Table 4-2, Fig.4-3). IOP changes in 
dexamtheasone-AR12286 and dexamethasone-suspension groups during the 
first four weeks were similar to dexamethasone-treated group, while IOP 
decreased in these two groups at week 5. At the endpoint, reduction of IOP in 
dexamethasone-treated group was significantly greater when compared to the 
control group (20.8±0.7 vs. 14.8±0.3 mm Hg, p < 0.0001, Mann-Whitney test). 
IOP was significantly reduced in dexamethasone- AR12286 group when 
compared to the dexamethasone-treated group (16.6±0.5 vs. 20.8±0.7, p < 
0.0001), but still significantly elevated when compared to the control (16.6±0.5 
vs. 14.8±0.3, p = 0.0176).  
Similarly, IOP was significantly reduced in dexamethasone-suspension 
group when compared to the dexamethasone-treated group (18.5±0.6 vs. 
20.8±0.7, p = 0.0184), but still significantly elevated when compared to the 
control (18.5±0.6 vs. 14.8±0.3, p < 0.0001). IOP was reduced significantly more 
in the dexamehtasone-AR12286 group when compared to dexamethasone-
suspension group (p = 0.0127). One week of AR12286 treatment reduced IOP by 
3.1 mm Hg, 15.7% of the IOP at week4. One week of suspension of 














0 14.2±0.3 14.6±0.5 14.5±0.3 12.9±0.4 
Week 1 14.3±0.3 19.0±0.5 18.7±0.4 16.9±0.5 
Week 2 13.7±0.3 18.9±0.7 20.1±0.3 18.7±0.6 
Week 3 14.0±0.4 21.8±0.8 20.6±0.5 20.2±0.7 
Week 4 14.0±0.4 20.0±0.6 19.7±0.4 20.3±0.6 
*Week 5 14.8±0.3 20.8±0.7 16.6±0.5 18.5±0.6 
 










Figure 4-3. Effects of Rho kinase inhibitor AR12286 and the suspension of 
dexamethasone treatment on elevated IOP.  
Dexamethasone treatment increased IOP over time. Dexamethasone-treated 
eyes showed significantly increased IOP at all time-points after treatment. In 
dexamethasone-AR12286 and dexamethasone-suspension groups, IOP 
changed similarly to the dexamethasone-treated group during the first four 
weeks, but IOP decreased in the last week with either the application of 
AR12286 or the suspension of dexamethasone treatment. Dexamethasone-
AR12286 group showed a more significant reduction in IOP when compared to 
dexamethasone-suspension group. Black arrow indicates the start of application 






Summary & Discussion 
The preliminary data of this study suggest that both topical Rho kinase 
inhibitor and suspension of dexamethasone treatment can rescue the steroid-
induced ocular hypertension. Rho kinase inhibitor is more efficient in IOP 
reduction than suspension of dexamethasone treatment. Therefore, topical Rho 
kinase inhibitor administration may help the patient with steroid-induced ocular 
hypertension/glaucoma reduce IOP more rapidly to avoid further damage to 
retina ganglion cells, especially for the patients who need to be continuously 
treated with steroid. However, further investigation will need to be conducted to 
reveal the effects of Rho kinase inhibitor on hydrodynamics and the morphology 
of trabecular outflow pathway in the steroid-induced ocular hypertensive mouse 
eyes. Analyses of TM PEFL, quadrant PEFL, TM thickness, JCT thickness, and 
ECM in TM will be needed as described previously. In addition, immunostaining 
of phosphorylated myosin light chain and type IV collagen will also be performed. 
The results of this study may help better understand the effects of Rho kinase 
inhibitor on eyes with elevated IOP, and further evaluate the possibility for Rho 
kinase inhibitor as a therapeutic method for steroid-induced ocular 
hypertension/glaucoma. 
Our preliminary data also showed that the shorter interval between two 
dexamethasone doses increased the IOP elevation effects. In the previous study, 
we applied the initial dose of topical dexamethasone between 9 am to 11 am 




treatment was around 4 mm Hg. However, in this preliminary study, we applied 
the initial dose between 8 am to 10 am while the second dose between 2:30 pm 
and 4:30 pm. An elevation by 6 mm Hg was found in the IOP in dexamethasone-
treated group, greater than that in the dexamethasone-treated group of the 
previous study. Therefore, application of dexamethasone with short intervals 
appears to have a greater IOP elevation side-effect. Extending the intervals 
between dexamethasone dosages may help avoid steroid-induced ocular 
hypertension/glaucoma. Meanwhile, a slight but not significant increase (p = 
0.08) in IOP of week 5 in the controls was shown by our preliminary data. This is 
possibly due to the stress caused to the animals when four dosages of daily 
manipulation was applied to them. 
 
4-3: Steroid-induced ocular hypertension is reversible by suspension of 
steroid treatment. 
Introduction 
 For the majority of patients with steroid-induced ocular hypertension, IOP 
usually returns to normal within 1 to 4 weeks after discontinuation of the steroid. 
We would like to know whether the steroid-induced ocular hypertension in mouse 
eyes is also reversible, and more importantly, whether the steroid-induced 
hydrodynamic and morphological changes are reversible. We used the 
dexamethasone-suspension group from the above study and kept monitoring 





The dexamethasone-suspension group (n=11) from above study was kept 
untreated after discontinuing dexamethasone treatment at the end of week 4. 
IOP was measured once each week between 8 am and 10 am. At the end of 
week 9, IOP returned and stabilized in the normal IOP range of mouse. One eye 
of each mouse was then injected with microbeads tracer to label the outflow 
pattern. The following hydrodynamic and morphological analyses were also 
performed as previously described. The results were compared to the results of 
saline-treated control from previous study (the endpoint was at week 5 for the 
controls).  
 Our preliminary data showed that IOP decreased in the dexamethasone-
suspension group after discontinuing the dexamethasone treatment and returned 
to the similar level of IOP of the control group at both baseline (14.3±0.4 vs. 
14.2±0.3 mm Hg, p = 0.59, Mann-Whitney test) and week 5 (14.8±0.3 mm Hg, p 
= 0.37) (Fig. 4-4). The outflow pattern in dexamethasone-suspension eyes was 
similar to that in control eyes (Fig. 4-5A). The average TM PEFL was 
76.27±5.01% (n=6), which was similar to that in the controls (77.74±2.73%, p = 
0.95, Mann-Whitney test) (Fig. 4-5B). When plotted TM PEFL versus IOP with 
dexamethasone-suspension group and the dexamethasone-treated and saline-
treated groups from the previous study, the data points of dexamethasone-










Figure 4-4. Effects of long-term suspension of dexamethasone treatment 
on elevated IOP.  
Suspension of dexamethasone treatment reduced the steroid-induced ocular 
hypertension. IOP of the dexamethasone-suspension eyes decreased over time 
after the treatment was discontinued (black arrow). IOP returned to the level 





















Figure 4-5. Suspension of dexamethasone treatment restores the TM PEFL 
in mouse eyes.  
A: Representative en face images of saline-treated and dexamethasone-
suspension eyes (N: nasal; T: temporal; S: superior; I: inferior). B: Suspension of 
dexamethasone treatment recovered TM PEFL to a similar level as controls. C: 
When plotted TM PEFL versus IOP, the data points of dexamethasone-
suspension eyes grouped with the control eyes, instead of dexamethasone-
treated eyes. D: When analyzed by quadrant, dexamethasone-suspension eyes 







Similar to control eyes, no quadrant preferences were found in TM PEFL in the 
dexamethasone-suspension eyes (superior vs. inferior, p = 0.68; superior vs. 
nasal, p = 0.44; superior vs. temporal, p = 0.31; inferior vs. nasal, p = 0.44; 
inferior vs. temporal, p = 1.00; nasal vs. temporal, p = 0.22; Wilcoxon signed rank 
test) (Fig. 4-5D). By multiple comparison analysis, there was no significant 
differences in TM PEFL in any quadrant between the dexamethasone-
suspension group and the control group (superior: p = 0.71; inferior: p = 0.09; 
nasal: p = 0.80; temporal: p = 0.73). The confocal images of radial (Fig. 4-6A) 
and frontal (Fig. 4-6B) sections revealed similar amounts of microbeads present 
in the TM region from high tracer regions when compared to that in the control. 
Similar to the control eyes, the average TM thickness in high tracer regions was 
significantly greater when compared to that in low tracer regions (19.18±0.80 vs. 
11.38±0.69 μm, p = 0.0043, Mann-Whitney test). Furthermore, TM thickness 
showed a significant increase in high tracer regions of dexamethasone-
suspension eyes when compared to that of controls (14.42±0.76 μm, p = 0.0016) 
(Fig. 4-7). Dexamethasone-suspension eyes showed no significant difference in 
JCT thickness when compared to the control eyes, both in high tracer (3.33±0.23 
vs. 3.05±0.54 μm, p = 0.42, Mann-Whitney test) and in low tracer (2.45±0.25 vs. 
1.92±0.17 μm, p = 0.15) regions. There were also no significant differences in 
JCT thickness between the high tracer and low tracer regions of dexamethasone-















Figure 4-6. Suspension of dexamethasone treatment restores the tracer 
amount in trabecular meshwork.  
Representative radial (A) and frontal (B) plane view confocal images reveal 
similar amount of microbeads tracer in the TM region with control after the 
suspension of dexamethasone treatment. The green represents the tracer 
distribution. The blue represents DAPI staining for the nuclei. (DEX: 














Figure 4-7. Suspension of dexamethasone treatment increases trabecular 
meshwork thickness.  
A: Representative radial plane view confocal images show the TM thickness 
measurements in high tracer vs. low tracer regions of control and 
dexamethasone (DEX)-suspension eyes.  B: In both dexamethasone-suspension 
and control eyes, TM thickness in high tracer regions was significantly higher 
when compared to low tracer regions. TM thickness in the high tracer regions of 
dexamethasone-suspension group also showed a significant increase when 












Figure 4-8. Suspension of dexamethasone treatment restores 
Juxtacanalicular Connective Tissue (JCT) Thickness.  
No significant difference in JCT thickness was found between dexamethasone-







analyses were not fully completed for the dexamethasone-suspension group, but 
curly collagen was observed in one out of five analyzed eyes. The increased 
deposition of fibrillary structure was observed in one low tracer region section in 
one out of five analyzed eyes. BM continuity will need to be further investigated. 
 
Summary & Discussion 
The preliminary data of this study suggest that IOP, hydrodynamics and 
morphology in trabecular outflow pathway are reversible in the steroid-induced 
hypertensive mouse eyes. After four weeks of topical dexamethasone 
administration, suspension of treatment for around five weeks allowed the IOP to 
return to the normal level. TM PEFL, especially the TM PEFL in the superior 
quadrant, also recovered to a similar level as the control eyes. The tracer amount 
in high tracer regions was found to be a similar level as in the control eyes. JCT 
thickness in the high tracer regions returned to normal level. However, some 
ultrastructure changes in the trabecular meshwork, such as the formation of curly 
collagen and the deposition of fibrillary structures, were not fully recovered. The 
expanding TM thickness in high tracer regions might be a compensation for 
these not fully recovered structures, in order to further reduce the resistance to 
aqueous outflow and restore the normal EFA in the trabecular meshwork 
pathway. It is also possible that if the dexamethasone-treated eyes were followed 
up for longer period of time after dexamethasone suspension, the remaining 




be reversed. Other ultrastructure changes, especially the BM continuity, will need 
further investigation. Our results provide another piece of evidence for the 
similarity between the steroid-induced ocular hypertensive mouse eye and the 
steroid-induced ocular hypertensive human eye,137 and further confirm this model 
to be valuable for studying the mechanism and therapeutic options for steroid-
induced ocular hypertension/glaucoma. Our findings demonstrate the reversibility 
of IOP, hydrodynamics, and morphology in the trabecular outflow pathway, 
indicating the possibility of reversing the pathological impairments in 
glaucomatous eyes and restoring the normal aqueous outflow by targeting the 
structures along the trabecular meshwork pathway. 
In clinic, not all individuals equally respond to glucocorticoids therapy. 
There are “steroid responders” who develop >6 mm Hg following topical steroid 
for 4-6 weeks,121,212 while non-responders with steroid resistance also exist.213,214 
Approximately 40% of the normal population are considered to be “steroid 
responders.” In contrast, almost all POAG patients are steroid responders.121 
Non-glaucomatous steroid responders are at higher risk for developing POAG 
compared to non-glaucomatous non-responders.122,123 A similar 40% responder 
rate was also found in nonhuman primates133 and ex vivo perfused bovine142 
eyes. However, other studies reported a 100% response rate when the cow and 
sheep received topical steroid.131,132 Interestingly, all C57BL/6J mice in our 
studies responded to the topical steroid, although the level of response may have 




groups of other investigators who used C57BL/6J mice.137,138,187,215 A previous 
study using a systemic steroid model showed that a small subset of mice with 
mixed C57BL/6J-Tyr(c-Brd) x 129S5/SvEvBrd (B6.129) background did not 
respond to the steroid, while IOP in most of mice elevated after dexamethasone 
treatment.136 This suggests that there may be mouse strain differences in 
glucocorticoids responsiveness. Recently a group of investigators reported 
nonresponsive to the topical dexamethasone in C57BL/6J mice.216 However, the 
mean baseline IOP in C57BL/6J mice reported by this study was greater than 
that reported by other groups (18 vs. 13-15 mm Hg), 136–138,187,215 and the 
reported body weight loss was ~20%, more similar to the body weight loss found 
in the previous systemic steroid study.  
Recently, novel dexamethasone delivery methods were developed for a 
steroid-induced ocular hypertensive mouse model, such as periocular 
conjunctival fornix injection of dexamethasone-21-acetate187 and 
subconjunctival/periocular injection of dexamethasone-encapsulated pentablock 
copolymer-based nanoparticles.215 These methods may further reduce the body 
weight loss caused by steroid treatment. While the former requires weekly 
injection of dexamethasone-21-acetate, the latter allows chronic release of 
dexamethasone from nanoparticles, and the IOP can be elevated for at least 





4-4: Thrombospondin 1 (TSP1) may be involved in steroid-induced ocular 
hypertension. 
Introduction: 
Thrombospondin-1 (TSP1) is an adhesive glycoprotein that mediates cell-
cell and cell-matrix interactions. TSP1 is a matricellular protein; and although it is 
a component of the ECM, it is not a primary structural element of the ECM, but 
rather interacts with cells, other ECM components, and growth factors to regulate 
cellular functions, growth factor activity, and assembly and structure of the ECM. 
TSP1 is present in the TM where it increases with age and is produced by TM 
cells in vitro.217–219 TSP1 may be involved in the glaucoma pathogenesis, 
because upregulated expression of TSP1 has been found in TM cells220 and 
lamina cribrosa cells221 at the optic nerve head in the glaucomatous eyes, which 
represent two major sites of pathology in glaucomatous eyes. Moreover, TSP1 
can be induced by mechanical forces on the TM, such as cyclic mechanical 
strain/stretch, which are characteristic of glaucoma.222 The IOP of TSP1-deficient 
mice is 10% lower when compared to corresponding wild-type (WT) mice,223 
indicating that TSP1 may be involved in IOP regulation. TSP1 was shown to 
influence ECM remodeling by affecting collagen production,224,225 activity of 
matrix metalloproteinases (MMPs),226–228 and transforming growth factor- β 
(TGF-β) signaling.229 We hypothesize that TSP1 may affect outflow resistance 
and contribute to IOP regulation via ECM remodeling. In order to investigate the 




staining of TSP1 and TGFβ2 in the steroid-induced ocular hypertensive mouse 
eyes to confirm the elevation of TSP1 and TGFβ2 expression in the TM. 
Furthermore, we applied topical dexamethasone treatment on the TSP1-deficient 
mice to test whether the TSP1 deficiency will result in an inhibition of steroid-
induced ocular hypertension. 
 
Preliminary Data 
 Five-micron transverse sections were obtained from three randomly-
selected eyes from each group: saline-treated, dexamethasone-treated, and 
dexamethasone-suspension. The paraffin sections were deparaffinized in xylene, 
rehydrated, and washed in PBS. All sections were then incubated for 30min in 
10% normal goat serum (Jackson Immuno Research Labs, West Grove, PA) in 
PBS at room temperature to prevent nonspecific binding. Sections were 
incubated overnight at 4oC with primary rat monoclonal antibody against TGFβ2 
(Clone # 771244; R&D Systems, Minneapolis, MN) at a dilution of 1:400. 
Sections were then rinsed three times with PBS for 15 minutes each, and 
incubated for 1 hour with CyTM 2-conjugated AffiniPure goat anti-rat secondary 
antibody (Jackson Immuno Research Labs) at a dilution of 1:200. Sections were 
rinsed in PBS, incubated for 1 hour in 10% goat serum at room temperature, and 
incubated overnight at 4oC with primary rabbit polyclonal antibody against TSP1 
(ab85762; Abcam, Cambridge, United Kingdom) at a dilution of 1:200. Sections 




rabbit secondary antibody (Invitrogen) at a dilution of 1:500. Both secondary 
antibodies were diluted in PBS containing 0.2% BSA. Sections were rinsed in 
PBS and mounted with DAPI Fluoromount-G mounting medium. Specimens were 
examined and imaged with Zeiss LSM 700. Negative controls were treated 
identically, except that the primary antibody was omitted. 
Our preliminary data showed that TSP1 and TGFβ2 expression was 
elevated in the TM of dexamethasone-treated eyes when compared to control. In 
the dexamethasone-suspension group, the eyes with IOP similar to the normal 
eyes showed lower level of TSP1 and TGFβ2 expression in the TM, while the 
eyes with relatively higher IOP showed higher level of TSP1 and TGFβ2 (Fig. 4-
9). 
To investigate whether dexamethasone elevates IOP via TSP-1 activation, 
15 TSP1-null mice (including both males and females) were randomly divided 
into two groups (dexamethasone-treated group, n=8, and saline-treated group, 
n=7). Similar to our previous study performed on WT mouse eyes, one small eye 
drop (∼10 μl) of either 0.1% dexamethasone phosphate or sterile saline was 
topically applied to both eyes of each mouse twice per day for 5 weeks. The 
initial daily dose was given between 8 am and 10 am, and the second dose 
between 2:30 pm and 4:30 pm. After initial baseline IOP measurement, IOP was 
measured weekly from all eyes between 8 am and 10 am using a rodent rebound 
tonometer. Each eye of a mouse was treated as an independent subject for IOP 




dexamethasone-treated TSP1-null group). At the endpoint of treatment, all eyes 
were enucleated and immersed into 4% paraformaldehyde at 4oC overnight. All 
eyes were then kept in PBS at 4oC for further processing. 
IOP data were also compared to saline-treated and dexamethasone-
treated WT mice (Fig. 4-10A). IOP in saline-treated TSP1-null mice was 
significantly lower at all time-points when compared to saline-treated WT mice 
(12.9±0.5 vs. 14.2±0.3 mm Hg, p = 0.0323 at baseline, 12.6±0.4 vs. 14.3±0.3, p = 
0.0037 at week1, 12.3±0.5 vs. 13.7±0.3, p = 0.0258 at week2, 11.7±0.5 vs. 
14.0±0.4, p = 0.0011 at week3, 12.3±0.4 vs. 14.0±0.3, p = 0.0030 at week4, and 
12.6±0.5 vs. 14.7±0.3, p = 0.0019 at week5, Mann-Whitney test), which was 
consistent with previously reported findings.223 While in WT mice, IOP in 
dexamethasone-treated eyes increased within a week, IOP in dexamethasone-
treated TSP1-null mice was similar to that in saline-treated TSP1-null mice at 
baseline (12.4±0.5 mm Hg, p = 0.52) and week1 (12.8±0.6, p = 0.97). The IOP 
was significantly increased at week2 when compared to the TSP1-null control 
(16.0±0.7, p = 0.0013) and reached the peak. The IOP then reduced over time, 
but was still significantly higher when compared to the IOP of TSP1-null control 
(15.4±0.6, p = 0.0005 at week3, 14.8±0.6, p = 0.0047 at week4, and 14.4±0.5, p 
= 0.0169 at week5). Due to the difference in baseline IOP between WT and 
TSP1-null mice, “IOP increased over control” (ΔIOP) was also calculated by 
using the IOP of dexamethasone-treated WT or TSP1-null eyes then subtracting 










Figure 4-9. Immunohistochemistry staining of TSP1 and TGFβ2. 
Immunohistochemistry staining showed elevated TSP1 and TGFβ2 expression in 
dexamethasone-treated mouse eyes when compared to saline- treated controls. 
In dexamethasone-suspension group, the eyes with IOP in normal range showed 
decreased TSP1 and TGFβ2 in the TM, while TSP1 and TGFβ2 expression were 
still elevated in the eyes with relatively higher IOP. (TM: trabecular meshwork; 














Figure 4-10. Dexamethasone-induced IOP elevation was partially inhibited 
in TSP1-null mice. 
A: Unlike WT mice, IOP in TSP1-null mice did not increase significantly until 
treated by dexamethasone for two weeks. IOP reached the peak at week2 in 
dexamethasone-treated TSP1-null mice but decreased afterwards. B: Except for 
the baseline, the increase of IOP in dexamethasone-treated TSP1-null mice was 







dexamethasone-induced IOP increase in TSP1-null mice was similar to that in 
WT mice at baseline (-0.48±0.48 vs. 0.38±1.01 mm Hg, p = 0.32). IOP increase 
in TSP1-null mice was significantly less than that in WT mice at week1  
(0.17±0.57 vs. 4.73±1.30, p < 0.0001). There was no significant difference in IOP 
increase between TSP1-null and WT mice at week2 (3.71±0.71 vs. 5.19±1.38, p 
= 0.35). The IOP increase in TSP1-null mice was again significantly less than 
that in WT mice at week3 (3.66±0.59 vs. 7.70±1.55, p = 0.0012), week4 
(2.53±0.63 vs. 5.81±1.40, p = 0.0012), and week5 (1.79±0.47 vs. 6.04±1.44, p = 
0.0002) (Fig. 4-10B). At its peak value at week2, the average of dexamethasone-
induced ΔIOP in TSP-1 null mice was 71.48% of that in WT mice. At week5, it 
was 29.64% of that in WT mice. 
 
Summary & Discussion 
 TSP1 was elevated in the TM of steroid-induced hypertensive mouse 
eyes. TSP1-null mice had a one-week delay in IOP elevation when compared to 
the WT mice. The peak elevation of IOP was lower in TSP1-null mice and post-
peak IOP was reduced over time. These preliminary data suggest that although 
TSP1-null mice are not completely resistant to steroid-induced ocular 
hypertension, TSP1 is playing an important role in IOP regulation.  
 TSP1 is a complex, multifunctional protein and among its diverse 
functions, its roles in ECM remodeling and actin-cytoskeleton remodeling are 




remodeling is associated with the abnormal accumulation of ECM and actin-
cytoskeleton remodeling may contribute to the increase of stiffness observed in 
TM of glaucomatous eyes. At least three different mechanisms may contribute to 
the role of TSP1 in ECM remodeling. First is its role as a major activator for 
TGFβ2. TGFβ2 is recognized as a central player in the pathology of glaucoma, 
and it stimulates ECM protein expression and secretion including that of TSP-
1.230,231 However, secreted TGFβ2 is present in the latent, inactive form and is 
unable to interact with its cellular receptors. This latent form can be activated in 
vitro and in vivo by TSP1.232,233 Consistent with the upregulation of TSP1 in 
glaucomatous eyes and the ability of TSP1 to activate the latent form of TGFβ2, 
enhanced levels of not only total but also active TGFβ2 have been reported in 
the aqueous humor of glaucomatous eyes.234 The overexpression of active 
TGFβ2 in mouse eye results in ocular hypertension.235 Therefore, TSP1 may 
stimulate ECM protein deposition and increase outflow resistance in the TM via 
TGFβ2 signaling. The second possible mechanism is that TSP1 influences the 
activity of matrix metalloproteinases (MMPs). MMPs are a group of enzymes that 
are capable of degrading all kinds of ECM proteins. The abnormal accumulation 
of ECM components is often time associated with suppression of MMPs 
activities. MMPs are constitutively expressed throughout the TM, with expression 
profiles responding to various stimuli.76,236,237 MMP protein expression is often 
upregulated in glaucomatous aqueous humor; however, activity is reduced in 




between MMPs with their tissue inhibitors, TIMPs.238–242 TSP1 has been shown 
to suppress the activation of both MMP-2 and MMP-9.228,227 TSP1-deficient mice 
show a defective upregulation of MMP-2.226 Therefore, TSP1 may reduce ECM 
turnover by suppressing MMPs activity. Thirdly, TSP1 may also affect the 
production of collagen, an important component of the ECM of TM, via a TGFβ2-
independent manner. 224,225 Therefore, TSP1 can induce the deposition of 
collagen in TM.  
A recent study showed that Smad3 deficiency resulted in a complete 
inhibition of steroid-induced ocular hypertension in mouse eyes.243 Smad3 is a 
protein downstream of the TGFβ2 signaling pathway. The authors concluded that 
TGFβ2 signaling may play a key role in steroid-induced ocular hypertension. 
Since TSP1-deficient mice only showed a partial inhibition in steroid-induced 
ocular hypertension while TSP1 is a major activator of TGFβ2, it indicates that 
there might be other alternative activators for TGFβ2 in the TSP1-deficient mice. 
However, reduced IOP was found in TSP1-deficient mice when compared to the 
WT mice,223 suggesting that TSP1 may also play a role in general IOP regulation, 
not limited to steroid-induced ocular hypertension. While Smad3 was shown to 
be necessary for TGFβ2-induced ocular hypertension in mouse eyes,244 there 
was no significant difference found between the Smad3-deficient mice when 
compared to the WT mice. These findings may suggest that Smad3 only plays a 




Further studies will be needed to understand whether delayed IOP 
elevation and lower peak elevation of IOP are the results of reduced collagen 
production and TGFβ2 signaling in TSP1-deficient mice, and whether the later 
reduction of IOP is caused by the increased activity of MMPs. Based on the IOP 
change curve, we hypothesize that there are time-dependent differences in ECM 
composition, morphology, TGFβ2 signaling, and activity of MMPs in the TM at 
week1, week2 and week5 between dexamethasone-treated TSP1-null mice and 
dexamethasone-treated WT mice. Further studies of immunohistochemistry 
staining and ultrastructural comparison in the high and low tracer regions of 
trabecular outflow pathway at different time points will be needed. These will 
include immunohistochemistry staining for TSP1, latent and activated forms of 
TGFβ2, MMPs, steroid-stimulated ECM components, such as collagen IV and 
fibronectin, and detailed functional and morphological comparison in the 
trabecular outflow pathway. The results of these studies will provide better 
understanding of the molecular mechanisms involved in IOP regulation and have 
the potential for developing novel therapeutic strategies by targeting TSP1 to 






CHAPTER FIVE: General Discussion 
 Previous studies suggest that EFA (assessed by PEFL) can serve as a 
critical morphometric parameter to correlate with outflow facility/IOP.57–59,61,62,64,65 
In these studies, we further investigated the morphological correlations in the 
trabecular outflow pathway that may regulate outflow facility/IOP via modulating 
EFA.  
I.  In the first study, a Rho kinase inhibitor, netarsudil, was used to 
increase outflow facility in an ex vivo human eye perfusion system. After using 
both global imaging and confocal microscopy to evaluate the tracer-labeled 
outflow pattern, netarsudil-induced outflow facility increase was found associated 
with an increased PEFL at both the inner wall of SC and ESV. Increased outflow 
facility induced by Rho kinase inhibitor was also observed in previous ex vivo 
perfusion studies using Rho kinase inhibitor Y27632 in bovine,58 monkey,59 and 
human61 eyes. The percentage increase in outflow facility in our study was 
59.70±13.65% at 3hr (Fig. 2-4), which is similar to the percentage increase in 
outflow facility observed in Y27632-treated eyes of bovine58(58.2 ± 18.9% at 
30min) and human61 (60.6 ± 16.9% at 3hr), but less than that observed in 
Y27632-treated eyes of monkey59 (114.9 ± 14.9% at 30min). 
Although no ex vivo perfusion data are available in bovine or monkey eyes 
with netarsudil treatment, a 53% increase in tonographic outflow facility in vivo in 
normotensive monkey eyes was previously found six-hour after topical 




study showed that a 22% increase in tonographic outflow facility in vivo in 
normotensive human eyes was induced by seven-day topical administration of 
one single dose of 0.02% netarsudil.157 Despite the difference between outflow 
facility measured in vivo and ex vivo due to the different methods utilized, the 
percentage outflow facility increase ratio between monkey and human was 
consistently around 2:1 when treated by Rho kinase inhibitors, both netarsudil 
and Y27632.  
The ex vivo perfusion data also suggest that longer duration of perfusion 
of Rho kinase inhibitor is necessary for human eyes to reach similar percentage 
outflow facility increase when compared to species with washout effect, such as 
bovine eyes, while still less when compared to monkey eyes. Although a 
significant increase in IW PEFL was previously found in bovine, monkey, and 
human eyes to be associate with the increased outflow facility, the IW PEFL 
increase in human eyes was 14.0% with netarsudil treatment (Fig. 2-5) and 
17.4% with Y27632 treatment,61 which are both less when compared to the IW 
PEFL increase in bovine (39.4%)58 and monkey (58.3%)59 eyes with Y27632 
treatment. 
Associated with this increase in IW PEFL after Y27632 treatment, JCT 
was found distended in bovine and monkey eyes, with loss of connections 
between JCT cells and between JCT cells and their ECM. A physical separation 
between IW and JCT was also observed in these eyes. The percentage 




have a significant positive correlation with relative increase in outflow facility (with 
respect to baseline) in bovine eyes (R2=0.518, p = 0.008)58 and with both the 
percent facility change (R2=0.376, p = 0.03) and IW PEFL (R2=0.93, p < 0.001) in 
monkey eyes59. Similar JCT distension and separation between IW and JCT 
were observed in bovine and monkey eyes with washout effects.59,60 The 
washout-induced increase in outflow facility was demonstrated to correlate with 
separation between the JCT and the basal lamina of the inner wall endothelial 
cells of aqueous plexus – anatomic structure in bovine eye functionally 
analogous to SC in human eyes.245,246 Therefore, the decrease of outflow 
resistance and increase of IW PEFL in Y27632-treated bovine and monkey eyes 
may also result from the loss of connectivity between IW and JCT. 
In human eyes perfused with netarsudil or Y27632 though, no distinct 
separation between IW and JCT was observed. But a significant increase in the 
JCT thickness in low tracer regions was found in human eyes treated with 
netarsudil (Fig. 2-8) or Y2763261 when compared to that in low tracer regions of 
control eyes. A significant positive correlation between IW PEFL and outflow 
facility, as well as between the loose JCT thickness and outflow facility, were 
found in human eyes perfused with Y27632. 61 Netarsudil was also shown to 
induce loss of actin stress fibers and cellular relaxation, loss of focal adhesions, 
which are the cell-matrix adhesions, in TM cells.105  
These data suggest that Rho kinase inhibitor induced distension of JCT in 




explain the smaller increase in IW PEFL and longer duration of perfusion with 
human eyes treated with Rho kinase inhibitor; however, they may still share 
similar mechanisms as bovine and monkey eyes for Rho kinase inhibitor-induced 
increases in IW PEFL. It is possible that the expansion of JCT as a result of 
cellular relaxation and loss of cell-matrix connectivity was responsible for the 
decrease of outflow resistance and increase of EFA in Rho kinase inhibitor-
treated human eyes. Compared to eyes having washout effects (bovine/monkey 
eyes), cell-cell and cell-matrix connections in TM may be stronger in human 
eyes, resulting in a less expandable TM structure. Our data also indicate that the 
increased IW PEFL induced by Rho kinase inhibitor treatment may have resulted 
primarily from its ability to change the more compacted JCT structure of low 
tracer regions to a looser or more expanded structure. When such morphological 
changes reach a certain degree of looseness, the previous low tracer regions 
could become medium or high tracer regions. This would result in an overall 
increase in the PEFL in the outflow pathway. Meanwhile, netarsudil induced an 
additional increase in PEFL at ESV when compared to that at IW, and PEFL at 
ESV showed a positive correlation with the outflow facility (Fig. 2-5). Increased 
cross-sectional area of ESV was found to be associated with the increased ESV 
PEFL (Fig. 2-7), indicating that the relaxation of smooth muscle around ESVs 
caused by Rho kinase inhibitor may result in a dilation of ESVs and lower the 




 II. In the second study, we used topical dexamethasone, a type of 
corticosteroid medicine, to increase IOP chronically in mouse eyes. After using 
en face confocal imaging to evaluate the tracer labeled outflow pattern, we found 
1) a reduced TM PEFL, associated with the increased IOP in dexamethasone-
treated eyes. 2) And the quadrant analysis showed that the most significant 
reduction in TM PEFL was in the superior quadrant (Fig. 3-4). Detailed 
morphological comparison was then performed between the high tracer and low 
tracer regions of dexamethasone-treated and untreated eyes using an imaging 
method that combines confocal, light, and electron microscopy. 3) We found a 
more compacted JCT structure, in the high tracer regions of dexamethasone-
treated eyes (Fig. 3-7). 4) Abnormal accumulation of ECM components, such as 
curly collagen and fibrillary structure, was found in the TM of dexamethasone-
treated eyes (Fig. 3-8).  
Both compacted JCT region and increased ECM may result in a loss in 
empty spaces in JCT, and a consequentially elevated local outflow resistance. 
Decreased empty spaces in TM was previously reported in systemic steroid-
induced ocular hypertensive mouse model.137 Meanwhile, dexamethasone was 
reported to induce focal adhesions in cell culture.191 The continuity of the 
basement membrane of inner wall endothelial cells was significantly increased in 
the high tracer regions of dexamethasone-treated eyes and had a significant 
negative correlation with the TM PEFL (Fig. 3-10), indicating that 




JCT may be responsible for the decrease in TM PEFL. Abnormal accumulation of 
ECM and increased BM continuity were also found in POAG and steroid-induced 
glaucomatous eyes.112,137 Our data also suggest that the decrease in TM PEFL 
induced by dexamethasone treatment may result from its ability to change the 
looser JCT structure and less IW-JCT connections of high tracer regions to a 
more compacted JCT structure with more IW-JCT connections. Therefore, 
previous high tracer regions could become medium or low tracer regions that 
results in an overall decrease in PEFL in the outflow pathway.  
Additional studies with dexamethasone-suspension showed that the 
morphological changes in TM were at least partially reversible (Fig. 4-8), and that 
the restored TM structure was associated with restored EFA (Fig. 4-5). Rho 
kinase inhibitor (AR12286) showed a greater restorative effect on IOP than 
suspension of dexamethasone treatment (Fig. 4-3). Our data also demonstrate 
that TSP1 may play a role in dexamethasone-induced ocular hypertension. Since 
TSP1 is known to modulate ECM via various mechanisms, this suggests that 
ECM remodeling within the tissues of the outflow pathway may play a critical role 
in the pathogenesis of steroid-induced ocular hypertension. 
 In summary, our results showed that the morphological changes within the 
tissues along the pathway regulates the trabecular EFA, which then results in an 
upregulation or down-regulation of aqueous outflow. One of the major sites of 
morphological modulation was seen at the TM, especially at JCT region, which is 




A more expanded JCT structure with less IW-JCT connections was found when 
EFA was upregulated, while a more compacted JCT structure with increased 
ECM and IW-JCT connections was found when EFA was down-regulated. These 
morphologic findings support the hypothesis that aqueous outflow is funneled 
through the TM.247 This hypothesis explains aqueous outflow resistance is 
because of pore funneling, a hydrodynamic coupling between the inner wall 
endothelium of SC and the JCT. The IW and JCT are anatomically adjacent to 
each other and aqueous outflow must cross the inner wall through discrete 
pores. Flow through the JCT is thereby confined to regions near the inner wall 
pores, forcing a funneling pattern of aqueous outflow (Figure 5-1A). The 
reduction in available area for flow generates outflow resistance in JCT region. 
Therefore, if IW-JCT connections are reduced, the funnel pattern would be lost 
and this would increase outflow (Figure 5-1B). Consistent with this theory are our 
findings that the majority of outflow resistance is generated within the JCT and 
that the attachment between the inner wall and JCT plays an important role in 
regulating outflow resistance. 
 Besides the structural and functional changes in TM, our netarsudil project 
revealed that outflow facility (or outflow resistance) was also modulated  by the 
morphological changes in the ESV, distal to the SC in the trabecular outflow 
pathway, another site that generates outflow resistance.7,46,47 The dilation of ESV 
further increased EFA in addition to the increase by TM modulation (Fig. 2-5, 2-









Figure 5-1. Illustration of Outflow Pattern through the Juxtacanalicular 
Connective Tissue (JCT) according to Funneling Hypothesis. 
A: To enter Schlemm’s canal, aqueous outflow must converge to pass through 
discrete openings along the inner wall, which decreases the available area for 
flow and increases outflow resistance in the JCT. B: Separation of the inner wall 
from the JCT eliminates the funneling pattern, increases the available area for 






 In conclusion, our data suggest that structural changes in trabecular 
outflow pathway can result in a change in EFA, which will affect the outflow 
facility/IOP consequently. Both the structural changes and consequential EFA 
changes could be at least partially reversible. Therefore, by therapeutically 
targeting changes in morphology that increase the EFA of the trabecular outflow 
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